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Abstract:  
Title: SerumCalprotectin levels as a marker of disease activity in children with Juvenile 
Idiopathic Arthritis 
Background:Juvenile idiopathic arthritis (JIA) is the most common chronic rheumatic 
disorder of childhood and encompasses a complex group of disorders comprising several 
clinical entities with the common feature of arthritis. Calprotectin is a calcium- and zinc-
binding protein that belongs to the S100 protein family and is released during the 
interaction of leucocytes with inflammatory activated endothelium at the sites of 
inflammation as occurs in JIA. We undertook this study to assess the usefulness of 
Calprotectin as a marker of disease activity in Indian children with JIA. 
Objectives: To assess the usefulness of serum Calprotectin levels as a marker of  
disease activity in children with JIA. 
Materials and methods: 121 children who fulfilled the International League of 
Associations For Rheumatology (ILAR) criteria for JIA were recruited into the study. 
Baseline demographic details were collected and Blood counts, ESR, CRP and 
Calprotectin levels were analyzed in all children after obtaining consent. Children were 
then divided into 2 groups based on disease activity as per Wallace criteria. Calprotectin 
levels were also analysed in 10 normal healthy children. Calprotectin levels 
weremeasured by using a ―Human Calprotectin Kit‖ which works on the basis of 
sandwich-enzyme linked immune sorbent assay technology (ELISA). 
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Results: 121 children with JIA were recruited into the study, 63 had active disease and 
58 had inactive disease. Systemic onset JIA constituted 42% of the study population and 
was the predominant disease subtype. Calprotectin levels were elevated in children with 
active disease compared to those with inactive disease. Mean Calprotectin value in active 
disease (3954ng/ml) was 2 fold higher than those with inactive disease (1899ng/ml) (p 
value ˂0.001)and 16 times higher than children who were normal healthy controls(mean 
of 233ng/ml). Area under curve for Calprotectin was 0.744 . For a cut off value of 1760 
ng/ml, Calprotectin had a sensitivity of 77% and specificity of 61% for assessment of 
disease activity in JIA. 
Conclusion: Serum Calprotectin levels was found to be a good marker of disease activity  
in children with JIA. However, further studies which involve serial monitoring of 
Calprotectin levels in a study population will provide additional information about 
accuracy of these markers.  
Keywords: Juvenile idiopathic arthritis, Calprotectin, disease activity. 
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INTRODUCTION 
 
Juvenile idiopathic arthritis (JIA) encompasses a complex group of disorders comprising 
several clinical entities with the common feature of arthritis. . It is not a single disease 
and encompasses different types of arthritis which has onset before the age of 16 years, 
symptoms last for more than 6 weeks and are of unknown cause. Each subtype of 
Juvenile Idiopathic Arthritis is characterized by distinct method of presentation, varied 
signs and symptoms, course and outcome. It is the most common chronic rheumatic 
disorder of childhood and is characterized by varied symptoms such as fever, joint pain, 
joint swelling, restriction of movements and can also involve other constitutional 
symptoms such as anorexia, weight loss and growth restriction. 
Even though, clinical criteria for JIA is fairly well defined, appropriate laboratory 
parameters for diagnosis and assessment of disease activity is still lacking. Current lab 
parameters being used in JIA include erythrocyte sedimentation rate, C-reactive protein 
(CRP), antinuclear antibody, rheumatoid factor (RF) and cyclic citrullinated peptide 
(CCP) antibody.JIA is a disorder in which inflammation is at the core of the pathogenesis 
of the disease and hence various biomarkers which serve as markers of inflammation are 
an area of active research in this condition. A biomarker is any molecule which can be 
measured in accessible patient material such as blood or urine, is easily measurable and 
remains stable over time and gives valuable information regarding various aspects of 
disease such as disease activity, prognosis and response to treatment. Various biomarkers 
are currently under research in children with JIA and one such biomarker is serum 
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Calprotectin. Calprotectin is a granulocyte and monocyte complex of calcium- and zinc-
binding proteins that belong to the S100 protein family and is released during cell 
activation and turnover. It is released during the interaction of leucocytes with 
inflammatory activated endothelium at the sites of inflammation as occurs in JIA. In 
recent years, few studies have reported the usefulness of Calprotectin as a marker of 
disease activity in children with JIA. But most of these studies incorporated only 1 or few 
subtypes of JIA. Studies from India which looked at Calprotectin levels in children with 
JIA are very few. Hence, we undertook this study to assess the usefulness of Calprotectin 
as a marker of disease activity in Indian children with JIA incorporating all the disease 
subtypes and also to compare Calprotectin with ESR and CRP which are currently the 2 
main investigations used for assessment of disease activity.  
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REVIEW OF LITERATURE 
 
JUVENILE IDIOPATHIC ARTHRITIS 
 
Juvenile Idiopathic Arthritis (JIA) is a term used to describe a clinically heterogeneous 
group of arthritides of unknown cause. It is not a single disease and encompasses 
different types of arthritis which has onset before the age of 16 years, symptoms last for 
more than 6 weeks and are of unknown cause. (1) Each subtype of Juvenile Idiopathic 
Arthritis is characterized by distinct method of presentation, varied signs and symptoms, 
course and outcome.  Previously, this condition was called Juvenile Chronic Arthritis or 
Juvenile Rheumatoid Arthritis (JRA). However, the currently accepted nomenclature 
internationally is Juvenile Idiopathic Arthritis (JIA). 
 
EPIDEMIOLOGY: 
 
JIA is the most common chronic rheumatic disorder of childhood.(1) In developed 
countries, it has a yearly incidence of 2–20 cases per 100,000 population and a 
prevalence of 16–150 cases per 100,000 population.(1)Worldwide incidence of JIA 
ranges from 0.8-22.6/100,000 children per year and prevalence ranges from 7-
401/100,000.(2) These wide ranging numbers are probably a reflection of population 
differences, environmental exposure and immunogenetic susceptibility, along with 
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variations in diagnostic criteria. Various studies showed that the rates of JIA were low in 
Asian population(3,4) and higher frequencies of JIA were noted in those of European 
descent(5,6). Different epidemiological studies have reported a wide variance in 
incidence and prevalence in different parts of the world. This might be attributed to 
various classification systems used in different studies, differences in data ascertainment 
or study design, difficulty in making accurate diagnosis and also because of paucity of 
trained pediatric rheumatologists worldwide. 
Thierry et al conducted a systematic literature review to identify the incidence and 
prevalence of JIA in Europe. They concluded that incidence rates varied from 1.6 to 23 
and prevalence from 3.8 to 400/100,000. (7)Oligoarticular JIA was found to be the most 
frequent form with pooled incidence rate 3.7 [3.5–3.9] and prevalence 16.8 [15.9–
17.7]/100,000). In Europe in 2010, the estimated number of incident cases was 6896 
[5481–8578] and 59,175 [44,256–76,983] prevalent cases.(7) 
Berntson et al showed that that the incidence of JIA in Nordic(Denmark, Finland, Iceland 
,Norway and Sweden) countries was 15 per 100,000 children per year.(8) A meta-
analysis done on various published epidemiological studies in JIA found that the 
prevalence ranged from 12 per 100,000 children in clinic-based studies to 132 per 
100,000 children in population-based studies.(9) 
Accurate data on the incidence and prevalence of JIA in India is currently lacking.A 
study done in India by Vishwanathakumar et al to study the clinical spectrum of JIA in a 
tertiary referral hospital, showed that polyarticular JIA was the commonest subtype 
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followed by pauciarticular JIA. In this hospital based study, 112 children with JIA were 
enrolled and 8.9% had systemic onset JIA,55.3% had polyarticular JIA and 35.7% had 
pauci articular JIA.(10) 
The incidence of JIA is more in girls than in boys, although the gender distribution varies 
with different subtypes(11). For example, the gender ratio is 2:1(females to males) in the 
Oligoarticular, polyarticular and psoriatic subtypes whereas the ratio is more equal in 
systemic JIA. In contrast more number of boys are affected in enthesitis related 
arthritis(12). Girls are found to be more affected in the subgroup associated with 
uveitis(13). 
 
CLASSIFICATION: 
 
Various nomenclature and classification systems have been proposed for childhood 
arthritis in the last  40 years.(14,15) The latest and widely accepeted classification system 
currently is that put forward by the International League Of Associations For 
Rheumatology in 1997 and revised in 2001. ILAR criteria divides JIA into 7 subtypes 
namely:  namely Oligoarticular arthritis, rheumatoid-factor [RF]- positive polyarthritis, 
RF-negative polyarthritis, systemic-onset JIA, psoriatic arthritis, enthesitis-related 
arthritis and undifferentiated arthritis.(14) 
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CLASSIFICATION OF CHRONIC ARTHRITIS OF CHILDHOOD: 
 
Table 1: 
Organisation EULAR (European 
League Against 
Rheumatism) 
ACR (American 
College of 
Rheumatology) 
ILAR (International 
League of Association 
For Rheumatology) 
Criteria Name Juvenile Chronic 
Arthritis 
Juvenile 
Rheumatoid 
Arthritis 
Juvenile Idiopathic 
Arthritis 
Year 1977 1986 1997,revised 2001 
Age of Onset < 16 years < 16 years < 16 years 
Duration ≥ 3 months ≥ 6 weeks ≥ 6 weeks 
Subsets 1.Pauciarticular <5 
joints 
2. Polyarticular: .4 
joints, RF- 
3. Systemic: arthritis 
with characteristic 
fever 
4. Juvenile 
rheumatoid arthritis: 
.4 joints, RF+ 
5. Juvenile ankylosing 
spondylitis 
6. Juvenile psoriatic 
arthritis 
 
1. Polyarthritis: ≥5 
inflamed joints 
2. Oligoarthritis 
(pauciarticular  
disease): <5 
inflamed joints 
3. Systemic onset: 
arthritis with  
characteristic fever 
 
 
1. Systemic 
2. Oligoarthritis 
a. Persistent 
b. Extended 
3. Polyarthritis: RF- 
4. Polyarthritis: RF+ 
5. Psoriatic arthritis 
6. Enthesitis-related 
arthritis 
7. Undifferentiated 
a. Fits no other 
category 
b. Fits more than one 
category 
 
Abbreviation : RF: Rheumatoid Factor 
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Table 2:Criteria for the Classification of Juvenile Rheumatoid Arthritis 
 
1. Age at onset: <16 yr 
2. Arthritis (swelling or effusion, or the presence of 2 or more of the following signs: 
limitation of range of motion, tenderness or pain on motion, increased heat) in ≥1 
joint 
3. Duration of disease: ≥6 wk 
4. Onset type defined by type of articular involvement in the 1st 6 mo after onset: 
Polyarthritis: ≥5 inflamed joints 
Oligoarthritis: ≤4 inflamed joints 
Systemic-onset disease: arthritis with rash and a characteristic 
quotidian fever 
5. Exclusion of other forms of juvenile arthritis 
 
*Modified from Cassidy JT, Levison JE, Bass JC, et al: A study of classification criteria 
for a diagnosis of juvenile rheumatoid arthritis, Arthritis Rheum 29:174–181, 1986. 
 
ETIOLOGY: 
 
The etiology is unknown. It is postulated to be multifactorial and appears to differ from 
one subset to another. It is considered to be an auto inflammatory disease(13). In 
conditions such as Oligoarthritis (antinuclear antibodies) and rheumatoid factor positive 
polyarthritis (IgM rheumatoid factor) where autoantibodies are common, humoral 
immune system seems to be central in the pathogenesis of the disease. In contrast, 
Enthesitis related arthritis , rheumatoid factor-negative polyarthritis, and psoriatic 
arthritis have relatively less tendency to autoantibody formation but have strong 
association with polymorphisms at the histocompatibility locus(16). The fact that genetic 
factors form only a part of the etiology is evidenced by the fact that familial 
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arthritis is very rare, although not unknown. In Juvenile Idiopathic arthritis, the 
fundamental pathological process is chronic inflammation, in which both the innate and 
adaptive immune systems play critical roles. In all categories of JIA, products of 
activated T cells and macrophages are involved in pathogenesis of synovitis. 
 
Various studies have also looked at environmental influences as a possible etiological 
factor. A Study done by Mason et al suggested that breastfeeding has a protective effect 
on the development of Juvenile Idiopathic Arthritis especially in Oligoarticular disease 
(17); however, a strong relationship was not confirmed in another study (18). A study 
done by Jaakkola et al suggested that maternal smoking during pregnancy is a risk factor 
for the development of arthritis in the first 7 years of life, especially in girls(19).In 
addition to diverse genetic predispositions, alterations in the immune responses, and 
different environmental triggers, the various theories of pathogenesis must also account 
various factors such as the  heterogeneity of the disease; the increase in prevalence of 
oligoarthritis, polyarthritis, and psoriatic arthritis in girls, as against the higher incidence 
of enthestis related arthritis  in boys; also of note is the narrow peak ages at onset for 
some types of arthrtis such as oligoarthritis, in contrast to the absence of a peak age at 
onset for systemic disease; and the association of extraarticular complications such as 
uveitis in certain disease subsets. Thus we can conclude that there may be multiple 
etiological events, or that the disorder may result from a single pathogenic vector which 
manifests itself in diverse clinical patterns based on its interactions with the host. It may 
be postulated that an environmental factor affecting a child with a specific genetic 
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predisposition, at a point of vulnerability which may be defined by age, intercurrent 
illness, hormonal abnormalities, psychological stress , immunological maturity, prior 
antigenic experience and trauma results in a clinical disorder. It is a complex interaction 
between all the above mentioned factors which leads to the causation of the disease. (13) 
 
PATHOGENESIS: 
 
JIA is an autoimmune disorder and is associated with alterations in humoral and cell-
mediated immune systems. T lymphocytes play a central role in the pathogenesis by 
releasing pro-inflammatory cytokines favoring a type 1 helper T-lymphocyte response. In 
JIA, there is also an increase in the recruitment of T lymphocytes specific for synovial 
non–self antigens. 
B-cell activation, immune complex formation, and complement activation also promote 
inflammation. Systemic disease and more severe articular disease may occur as a result of 
upregulation of certain inflammatory networks due to the inheritance of specific cytokine 
alleles by the affected individual.(2) 
 
Systemic Onset Juvenile Idiopathic arthritis is characterized by dysregulation of the 
innate immune system and a lack of autoreactive T cells and autoantibodies. It is thus 
classified as an auto inflammatory disorder.  
 
The complex interaction between various immunologic abnormalities, genetic 
predisposition coupled with environmental triggers cause inflammatory synovitis which 
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is characterized pathologically by villous hypertrophy and hyperplasia with hyperemia 
and edema of the synovial tissue. There is also presence of vascular endothelial 
hyperplasia which is characterized by infiltration of mononuclear and plasma cells with a 
predominance of T lymphocytes. In advanced and uncontrolled disease, pannus formation 
and progressive erosion of articular cartilage and contiguous bone occurs (2). 
 
VARIOUS SUBTYPES OF JIA: 
 
OLIGOARTICULAR JIA: 
 
 
Oligoarticular juvenile idiopathic arthritis (JIA) is defined as a chronic inflammatory 
arthritis of unknown origin that has onset before the age of 16 and persists for at least 6 
weeks.It is further divided into persistent and extended Oligoarticular JIA.The term 
persistent is used if no more than four joints are affected during the disease course and 
the term extended is used if, after the initial 6-month period, the total number of affected 
joints exceeds four. The International League of Associations for Rheumatology (ILAR) 
classification also requires that patients who otherwise fulfill these criteria be excluded 
from the category if the patient has psoriasis, or if there is a history of psoriasis or a 
disease associated with the human leukocyte antigen (HLA) allele HLA-B27 in a first-
degree relative; if the disease began in a male older than 6 years of age; or if two positive 
tests for rheumatoid factor (RF) were obtained at least 3 months apart. (20) 
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The peak incidence of oligoarthritis is between 1 and 3 years of age and Oligoarticular 
JIA is the most common cause of chronic oligoarthritis in girls younger than 6 years of 
age .The first 6 months of disease is characterized by inflammation in four or fewer 
joints. Children are not usually systemically ill, and, except for chronic uveitis, 
extraarticular manifestations are distinctly unusual. In oligoarthritis, the affected joint is 
swollen and often warm, but usually not very painful or tender, and almost never red. 
Varying degrees of effusion may be present.  Oligoarticular JIA is predominantly a 
disease of the lower extremities.In at least half of the reported cases, only a single joint is 
affected (monoarticular onset), usually the knee. Uveitis may be present at onset of the 
disease; it eventually affects up to 20% of children and is usually asymptomatic. 
 
Laboratory indicators of inflammation may be normal in children with oligoarthritis, 
although mild to moderate elevation of acute phase reactants (ESR and CRP) may occur. 
Blood counts are usually normal. Tests for rheumatoid factor is almost always negative, 
although occasionally children with a single affected joint (often the wrist) have 
rheumatoid factor. ANA is  positive in low to moderate titer (1 : 160 to 1 : 640) in 62% to 
65% of children with oligoarthritis, particularly in girls and in those with uveitis(21). 
Antibodies to histones are present in 6% of children with Oligoarticular JIA and 12% in 
those with uveitis(22).Antibodies that react with citrullinated peptides have rarely been 
demonstrated in children with oligoarthritis 
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POLYARTICULAR JIA: 
Chronic childhood arthritis affecting 5 joints or more in the first 6 months of disease is 
defined as polyarthritis.The International League of Associations for Rheumatology 
(ILAR) classification system for juvenile idiopathic arthritis (JIA)2 further categorizes 
polyarthritis as rheumatoid factor (RF) negative if tests for RF are negative, and RF 
positive if RF is detected on two occasions at least 3 months apart(20). Polyarthritis is 
present in 20% of JIA patients; of these, approximately 85% have negative tests for 
rheumatoid factor. RF-negative polyarticular JIA can begin at any age before 16 years, 
but onset age displays a biphasic trend with a peak at ages 1 to 3 years and another peak 
between childhood and adolescence.(23)Girls are four times more frequently affected 
than boys in RF-negative polyarthritis. The mean age at juvenile onset of RF-positive 
polyarthritis is 9 to 11years, and the range is 1.5 to 15 years (13) .  
Joint disease predominates in children with RF-negative polyarticular JIA and 
extraarticular features are infrequent. Wrists and ankles are most commonly affected in 
these children and small joint involvement of the hands or feet usually occurs.The 
temporomandibular joint (TMJ) is commonly affected in children with a polyarticular 
disease course regardless of onset subtype. Systemic manifestations in seronegative 
polyarticular JIA are unusual and if present can include fatigue and growth failure. Fever 
seldom occurs and when present is low grade. ANA can be present in approximately half 
of the patients with RF negative polyarticular JIA. 
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SYSTEMIC ONSET JUVENILE IDIOPATHIC ARTHRITIS: 
Systemic arthritis is definedby the ILAR classification of juvenile idiopathic arthritis 
(JIA)based on the following criteria: presence of arthritis and a documented quotidian 
fever of at least 2 weeksduration plus one of the following: typical rash, generalized 
lymphadenopathy, enlargement of liver or spleen, or serositis. It can occur at any time 
during childhood with a peak age of onset between 1 and 5 years. Boys and girls are 
equally affected(13). 
 
In systemic onset JIA there is profound activation of the innate immune system which 
results in elevated levels of several inflammatory cytokines such as IL-1, IL-6, IL-8, IL-
18 and tumor necrosis factor, all of which play a major role in the pathogenesis. Systemic 
JIA is characterized by arthritis, fever, rash, and presence of visceral involvement such as 
hepatosplenomegaly, lymphadenopathy, and serositis such as pericarditis. Fever in 
systemic JIA is usually high grade and usually≥39°C (102.2°F) and occurs on a daily or 
twice-daily basis for at least 2 week, with a rapid return to normal or subnormal 
temperatures. The fever is often present in the evening and is frequently accompanied by 
a characteristic faint, erythematous, macular rash. Rash most commonly occurs on the 
trunk and proximal extremities but may also develop on the face, palms, or soles. The 
rash tends to be migratory, is usually non pruritic and is strikingly evanescent in any one 
area and disappears within a few hours and leaves no residua. Rash also exhibits koebner 
phenomena which is a cutaneous hypersensitivity reaction in which classic lesions are 
brought on by superficial trauma.  
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The cluster of fever, rash, hepatosplenomegaly, and lymphadenopathy is present in more 
than70% of affected children. Some children present initially with only systemic features 
and no arthritis. However, arthritis evolves over time and is essential for a definitive 
diagnosis. Arthritis may affect any number of joints. The course is classically 
polyarticular, may be very destructive, and can include hip, cervical spine, and 
temporomandibular joint. 
The most dreaded complication of systemic onset JIA is the development of macrophage 
activation syndrome (MAS) and can occur at any time during the disease course. MAS is 
also referred to as secondary hemophagocytic syndrome or hemophagocytic 
lymphohistiocytosis (HLH). The predisposition of individuals with systemic JIA to 
develop MAS may be associated with cytolytic pathway defects and is usually linked to 
heterozygous mutations in some of the genes associated with primary HLH such as 
PRF1, MUNC13-14, LYST, and STXBP2, as well as to high levels of proinflammatory 
cytokines such as IL-6. (13) 
MAS is characterized clinically by the rapid development of high unremitting fever, 
hepatosplenomegaly, lymphadenopathy, hepatic dysfunction, encephalopathy and skin 
and mucosal bleeding manifestations. Patients can develop multiorgan involvement and 
may progress to respiratory distress, renal failure, disorientation, seizures, and 
reducedlevel of consciousness, hypotension, and shock. Macrophage activation syndrome 
is associated with high mortality and morbidity and requires prompt treatment(2). 
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Laboratory studies may show low hemoglobin levels with thrombocytopenia. Typically, 
liver enzymes, lactate dehydrogenase (LDH), triglycerides, and ferritin levels are 
elevated. Extreme hyperferritinemia with levels above 10,000 μg/L is characteristic, and 
serum albumin is low. D-dimers levels are elevated and prothrombin time (PT) and the 
partial thromboplastin time (PTT) may be prolonged. The erythrocyte sedimentation rate 
(ESR) may drop sharply in association with hypofibrinogenemia, but C-reactive protein 
(CRP) is typically elevated. Demonstration of hemophagocytosis in the bone marrow or 
other tissues is diagnostic, but MAS may occur in the absence of demonstrated tissue 
hemophagocytosis in up to 40% of patients. The features that were decided by an 
international consensus panel as the most important indicators of MAS include a falling 
platelet count, extreme hyperferritinemia, evidence of macrophage hemophagocytosis in 
the bone marrow, increased liver enzymes, falling leukocyte count, persistent, continuous 
fever ≥38°C (100.4°F), falling ESR, hypofibrinogenemia, and hypertriglyceridemia. 
 
ENTHESITIS RELATED ARTHRITIS: 
It is predominantly a disease affecting joints and entheses of the lower extremities and 
can eventually affect the spine or sacroiliac (SI) joints. It is characterized by the absence 
of rheumatoid factor (RF) and by a strong association with the human leukocyte antigen–
B27 (HLA-B27). ERA affects 11–16% of children with JIA. In the past this type of JIA 
was called juvenile ankylosing spondylitis, seronegative enthesopathy and arthropathy 
(SEA) syndrome, or undifferentiated juvenile spondylarthropathyThe mean age at 
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diagnosis is around 10 to 13 years (range 2.8 to 17.6 years) and boys are more affected 
than girls. 
Enthesitis is defined as  localized inflammation at the point of insertion of tendons, 
ligaments, joint capsules, or fascia to bone (11). The typical locations for enthesitis are in 
the lower limbs and areas commonly involved are the iliac crest, posterior and anterior 
superior iliac spine, femoral greater trochanter, ischial tuberosity, patella, tibial 
tuberosity, Achilles, and plantar fascia insertions. ERA should be considered in patients 
presenting with significant heel or foot pain. Another unique feature of this subtype of 
JIA is the involvement of the axial skeleton, especially in the sacroiliac joints, with some 
children developing ankylosing spondylitis within 10 to 15 years of disease onset. 
 
 
CLINICAL MANIFESTATIONS: 
 
Constitutional Signs and symptoms:  
 
Anorexia, weight loss, and growth failure occurs in many children with Juvenile 
Idiopathic arthritis. Children with polyarticular or systemic disease have significant 
fatigue, especially at disease onset and during periods of poor disease control. Fatigue 
may be manifested as an increased sleep requirement, lack of energy, or increased 
irritability. Night pain may be present although it is more characteristic of malignancy. 
However, night pain can interrupt sleep and contribute to fatigue. 
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Anorexia may occur as a result of gastric irritation secondary to nonsteroidal 
antiinflammatory drug use, or nausea secondary to methotrexate use. 
Growth retardation may occur as a consequence of active JIA and can also be attributed 
to prolonged corticosteroid use. Puberty and secondary sexual characteristics are often 
delayed in children with active inflammation. 
 
Pain and stiffness: 
A child with chronic arthritis may not complain of pain at rest. However, if the joint is 
inflamed, active or passive motion of a joint elicits pain especially at the extremes of 
range of motion. Pain can be mild, moderate or rarely severe in severity and is usually 
described as an aching or stretching type of pain. Pain elicited by pressure (tenderness) 
is maximal at the joint line.Bone pain or tenderness is not a characteristic feature of 
arthritis, and if it is present, the possibility of an infection or malignancy involving the 
bone should be considered. 
 
Joint stiffness is a characteristic symptom exhibited by most children with Juvenile 
Idiopathic arthritis. Joint stiffness is more profound in the morning particularly on arising 
from bed or after prolonged inactivity. Parents usually describe stiffness as slowness or 
awkwardness of the gait which is most marked in the morning or after a nap or prolonged 
sitting and which improves with activity or heat application to the affected area. Stiffness 
which lasts for more than 15 minutes signifies a considerable level of joint inflammation.  
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Features of Inflamed Joint:   
The cardinal signs of inflammation that actively inflamed joint exhibits are: Swelling, 
pain, heat, loss of function, and erythema. Swelling of a joint usually occurs as a result of 
edema of the periarticular soft tissue or because of intraarticular effusion, or from 
hypertrophy of the synovial membrane. Large synovial cysts are unusual and may occur 
in the antecubital area or anterior to the shoulder. When they occur in the popliteal space, 
it is called a baker cyst. 
Inflamed joints in children with juvenile idiopathic arthritis areoften warm but almost 
never erythematous. In contrast, joints in septic arthritis or acute rheumatic fever will be 
erythematous.There is limitation of range of movements, particularly in 
extension,because this is usually a position of relative comfort, accommodating shortened 
soft tissue structures. Hyperextension is characteristicallythe first range of movement to 
be lost in the cervical spine. Similarly, extension or hyperextension is first lost in elbows, 
wrists, metacarpophalangeal and interphalangeal joints, but flexion range can also be 
diminished. 
The hallmark symptom of intraarticular hip joint disease is loss of internal rotation and 
flexion. Loss of hyperextension or extension, and sometimes flexion occurs if the knees 
are affected. Loss of ankle dorsiflexion, subtalar eversion, and midfoot supination are 
characteristic of an inflamed joint.  
 
 
 
30 
 
Ocular Involvement: 
Ocular inflammation may occur at any time in the course of Juvenile Idiopathic Arthritis. 
Uveitis is characteristically asymptomatic in most cases, except in enthesitis related 
arhritis, where it is characterized by a painful pink eye.  Keratoconjunctivitis sicca 
occasionally occurs, particularly in patients with rheumatoid factor-positive polyarthritis 
 
Distribution Of affected Joints: 
Any joint can be affected in Juvenile Idiopathic arthritis. Most frequently involved joints 
are the large joints such as knees, ankles, wrists, elbows and hips. Small joints of the 
hands and feet can also be affected, especially in cases of polyarticular-subtype of 
disease. Disease in the apophyseal joints of the cervical spine are rare and occurs at onset 
in only 2% of children. These children may present with torticollis.The 
acromioclavicular, sternoclavicular, and sternomanubrial joints are 
infrequently affected. 
 
Various subtypes of Juvenile Idiopathic Arthritis have different characteristic patterns of 
joint involvement. In, polyarticular disease, symmetrical involvement of large and small 
joints is typical. Patients with Enthesitis related Arthritis (ERA) have predominantly 
involvement of the joints of the lower extremity. The presence of hip joint disease is not 
uncommon in ERA, but rarely occurs in Oligoarticular JIA. Patients with Psoriatic 
arthritis have a somewhat asymmetrical involvement and involves both large and small 
joints, sometimes including the distal interphalangeal joints. 
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LABORATORY FEATURES: 
 
Laboratory parameters are used toprovide support for a diagnosis of chronic arthritis. No 
laboratory test or combination of studies can confirm the diagnosis of Juvenile Idiopathic 
arthritis. Laboratory parameters can be used to provide evidence of inflammation, to 
monitor toxicity of therapy, and as a research tool to understand more completely the 
pathogenesis of the disease 
 
Hematological Indices: 
Hematologic abnormalities often reflect the degree of systemic or articular inflammation.  
Children with involvement of only a limited number of joints usually do not exhibit any 
hematological aberrations beyond that of mild anemia.Normocytic hypochromic anemia 
is usually found in children with moderately extensive arthritis. In children with severe, 
uncontrolled disease, the anemia may be severe with hemoglobin in the range of 7 to 10 
g/dL. The cause for anemia in these children is due to chronic disease; however, iron 
deficiency may also play a role as plasma iron transport and iron available for 
erythropoiesis are decreased in systemic disease. 
 
Leukocytosis is usually found in children with active juvenile idiopathic arthritis in all 
disease subtypes. Values are strikingly high in children with systemic- onset disease and 
are usually in the range of 30,000 to 50,000 to cells/mm3 (30 to 50 × 109/L). 
Thrombocytosis is commonly found and the platelet count may rise dramatically in 
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children who have long standing disease or those with severe disease. Thrombocytosis 
can also occur during disease exacerbation. Thrombocytopenia is rare and may signal an 
evolution of the disease into systemic lupus erythematosis, drug toxicity, or the 
development of macrophage activation syndrome. 
In the setting of Macrophage activation syndrome, all cell lines such as hemoglobin, 
white blood cells and platelets have the propensity to decline precipitously owing to the 
consumptive process. A low or normal white blood cell count along with a dropping 
platelet trend in a child with active systemic onset juvenile idiopathic arthritis should 
raise the concern of macrophage activation syndrome. 
 
ACUTE PHASE REACTANTS: 
Acute phase reactants such as ESR and CRP are elevated in children with juvenile 
idiopathic arthritis. Erythrocyte sedimentation rate (ESR) reflects the plasma fibrinogen 
level and is a useful measure of disease activity at onset of disease and during follow-up 
of a child with arthritis. Similarly, C-reactive protein (CRP) level is also a reliable marker 
of inflammatory response. 
 
The third component of complement (C3) isan acute phase protein and is often elevated 
in the sera of children with active disease. The activated form of the molecule 
(C3d) may be increased as well and is an indicator that complement-mediated tissue 
damage plays a role in the pathogenesis of arthritis in children. 
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Ferritin is an acute phase reactant which can be grossly elevated in children with arthritis. 
Its values are strikingly high and is usually more than 10,000 ng/ml in those with 
macrophage activation syndrome.  
 
Serum immunoglobulin levels are also increased in children with arthritis and its levels 
correlate with disease activity. Extreme hypergammaglobulinemia can bepresent in very 
sick children and returns toward normal with clinical improvement. 
 
Synovial fluid from patients with juvenile idiopathic arthritis is usually inflammatory. 
The main components of the synovial fluid in inflamed joints are polymorphonuclear 
neutrophilsand mononuclear cells, including lymphoid dendritic cells.As in adult 
rheumatoid arthritis,synovial fluid levels of glucose may be low. Likewsie, complement 
levels are not as uniformly depressed as inadult disease. The concentration of 
glycosaminoglycans such as hyaluronic acid and chondroitin sulfates in synovial 
fluid is decreased compared with normal controls, accounting for the low viscosity of 
inflamed synovial fluid. 
 
 
Radiologic Features: 
Early radiographic features of arthritis include soft tissue swelling, periarticular 
osteopenia, and periosteal new-bone apposition around joints that are affected. 
Continuation of active disease may lead to subchondral erosions, loss of cartilage, 
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varying degrees of bony destruction, and fusion. Characteristic radiographic changes in 
cervical spine aremost frequently located in the neural arch joints at C2-C3 and may 
progress to atlantoaxial subluxation. MRI is the imaging of choice to detect early 
changes. 
TREATMENT: 
PHARMACOLOGIC THERAPY: 
Juvenile Idiopathic arthritis is a disorder that cannot yet be cured. However, control of the 
disease is achievable with medications. The aim of treatment is to induce disease 
remission, and in the process to control pain and preserve range of motion, strength of the 
muscle and its function. Therapy is also used to manage systemic complications; and to 
facilitate normal nutrition, growth, and physical and psychological development. Most 
children with JIA often are in need of a therapy which is a combination of 
pharmacological, physical, and psychosocial approaches.  Patients with JIA need 
individualized treatment plans, and therapy is modified based on disease subtype and 
severity, presence of poor prognostic indicators, and response to medications. Monitoring 
for potential drug toxicities is also an intrinsic part of disease management. 
 
Nonsteroidal anti-inflammatory drugs (NSAIDs) have been the traditional initial 
approach in the management of children with Juvenile Idiopathic arthritis. Those children 
with oligoarthritis subtype often show only partial response to nonsteroidal 
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antiinflammatory drugs (NSAIDs), with improvement in inflammation and pain 
.Thosewho have functional limitations, such as joint contracture or leg-length 
discrepancy and those who have no or partial response after 4-6 wk of treatment with 
NSAIDs often benefit from injection of intraarticular corticosteroids. Triamcinolone 
hexacetonide is a long-lasting medication that is often used and provides response for a 
prolonged period of time. There will be a minority of patients with Oligoarticular subtype 
of JIA who would not respond to NSAID’s as well as intraarticular injections. This 
minority of patients require treatment with disease-modifying antirheumatic drugs 
(DMARDs), methotrexate, 
and, if no response, then TNF inhibitors. 
 
Children with polyarthritis and systemic onset JIA are usually more symptomatic and 
NSAIDs alone rarely induce remission in them. DMARD which is the oldest and least 
toxic which is available for adjunctive therapy is Methotrexate. It usually takes 6 to 12 
weeks to exhibit its effects. If monotherapy with Methotrexate fails, then, it warrants 
theaddition of a biologic DMARD. Biological medications are drugs which inhibit 
proinflammatorycytokines, such as TNF-α, IL-1, and IL-6 and have excellent disease 
control. TNF-α antagonists such as Etanercept and Adalimumabare used to treat children 
with an inadequate response to methotrexate and thosewith poor prognostic factors, or 
severe disease onset. Commencement of early aggressive therapy with a combination of 
methotrexate and aTNF-α antagonist may result in the achievement of disease remission 
earlier than usual. 
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Systemic symptoms predominate in children with systemic onset JIA and TNF inhibition 
is not as effective for the control of the same. Systemic steroids are started when systemic 
symptoms predominate followed by the initiation of IL-1 or IL-6 antagonist therapy, 
which often induces a dramatic and rapid response. That subset of patients with severe 
disease activity may directly have to be started on treatment with Anakinra. Two FDA-
approved drugs which can be used for treatment of children with systemic onset JIA older 
than 2 years of age are Canakinumab which is an IL-1β inhibitor, and tocilizumab which 
isan IL-6 receptor antagonist. 
The use of systemic corticosteroids can often be avoided or minimized with the advent of 
newer DMARDs. Systemic steroids should be used only for the management of severe 
systemic illness and as a bridge therapy while awaiting therapeutic response to a 
DMARD, and for control of uveitis. Use of high dose steroids is associated with severe 
side effects such as Cushing syndrome, growth retardation, and osteopenia, and they 
cannot prevent joint destruction. 
Another class of drugs known as Oral Janus kinase (JAK) inhibitors such as tofacitinib, 
and ruxolitinib inhibit JAK signaling pathways involved in immune activation and 
inflammation. Tofacitinib is an FDA approved medication for adults with rheumatoid 
arthritis. 
Asymptomatic uveitis is often found in children with JIA periodic slit-lamp 
ophthalmologic should form a part of the management process to monitor for the same. 
Optimal management of uveitis involves a collaborative effort between the 
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ophthalmologist and rheumatologist. Initial treatment of uveitis is with mydriatics and 
corticosteroids which can be used topically, systemically, or through periocular injection. 
Methotrexate and antibodies to TNF-α (adalimumab and infliximab) are effective in 
treating severe uveitis. 
 
NUTRITION AND OCCUPATIONAL THERAPY: 
 
Various studies have documented different degrees of undernutrition or obesity in 
children and adolescents with JIA.Assessment of nutritional status should be an integral 
component of every patient’s evaluation.Retardation of growth and impairment of bone 
mineralization invariably occur during periods of active disease and are exacerbated by 
glucocorticoid administration, anorexia, or inanition. Supplementation of calcium, 
vitamin D, and folic acid is oftenindicated in children undergoing treatment for JIA. 
 
Physical therapy and occupational therapy are invaluable adjuncts to any treatment 
program and its objectives are to minimize pain, maintain and restore function, and 
prevent deformity and disability. Treatment team should also ideally include a social 
worker and nurse clinician who act asimportant resources for families, to recognize 
stresses imposed by a chronic illness and to identify appropriate community resources, 
and also aid compliance with the treatment protocol. 
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BIOMARKERS IN JUVENILE IDIOPATHIC ARTHRITIS: 
 
A biomarker is a molecule which can be easily measured in accessible patient material 
such as blood, urine or saliva, and is ideally obtained using a relatively non-invasive 
approach. The components used as a biomarker should ideally be stable over time within 
the patient sample and should be able to be measured by an accurate, easy to use and 
reproducible assay and at an affordable cost to the patient as well as the health care 
providers.(24) .An ideal biomarker for pediatric use would be one whose normative 
values are not affected by age related development in children, thus avoiding the need for 
age specific normal-range data sets.  Biomarkers are being increasingly used in various 
areas of clinical practice for assessment of disease activity and to help aid in the choice of 
treatment and for prognostication. However, most of these studies are done in adults and 
the data from these studies are extrapolated to children without considering differences in 
disease pathogenesis, age dependent changes in reference values owing to growth and 
development in children over time, effect of ontogeny on disease evolution and response 
to treatment, and changes in phenotypic gene expression.(25, 26) 
Use of biomarkers in JIA is a rapidly expanding field as pediatric rheumatologic diseases 
present inherent challenges in initial diagnosis and continued monitoring of disease 
activity. At disease onset, characteristic symptoms may take time to accumulate, and 
diagnoses are frequently of exclusion. Patients then may go on to have subclinical 
inflammation or relapsing disease. The scope of pediatric biomarkers in JIA is huge but 
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despite this, there are no validated pediatric biomarkers available to aid in setting up a 
cornerstone on which disease activity can be predicted or drug choice can be based.   
 
JIA is a heterogeneous group of disorders which uses both clinical findings and some 
biomarkers to divide cases into its various subtypes. Polyarticular form of JIA which 
involves five or more joints in the first six months of disease is divided into its 2 subtypes 
(Rheumatoid factor positive and rheumatoid factor negative) based on the presence or 
absence of a serum autoantibody called rheumatoid factor (RF). These 2 clinical subtypes 
are in turn different from each other with respect to their  genetics, age of onset and 
prognosis.(27,28). Similarly, the presence of positive serum Anti-Nuclear Antibody 
(ANA)  has been associated with an increased risk of chronic anterior uveitis(29), which, 
if not screened properly and treated, can result in permanent visual loss.(30, 31) Thus, 
both these antibody biomarkers (RF and ANA) can be easily measured in serum and 
currently are part of routine clinical care in management of children with JIA.  
 
A study done by Gilliam et al in children with JIA measured the levels of a panel of 
biomarkers which included cartilage oligomeric matrix protein (COMP), anti-cyclic 
citrullinated peptide (anti-CCP) antibodies, ), IgM rheumatoid factor (RF), IgG RF, and 
IgA RF, C-reactive protein (CRP) and erythrocyte sedimentation rate (ESR). They found 
significantly elevated levels of IgA RF, IgM RF, and anti-CCP antibodies in patients with 
joint erosions and joint space narrowing which are markers of aggressive disease. COMP 
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levels were elevated in early course of disease whereas ESR, CRP, and IgA RF were 
significantly elevated in patients with active synovitis. (32) 
 
Ferritin is a biomarker that is elevated in conditions associated with acute inflammation 
such as rheumatoid arthritis and systemic lupus erythematosis. In these conditions, it 
usually rises in parallel with other acute phase reactants. However, in children with 
systemic onset Juvenile idiopathic arthritis (SOJIA), ferritin levels are noted to be 
extremely high and exceed 1000 ng/ml whereas the normal range of ferritin is between 7-
140 ng/ml (33,34) and thus may be helpful in establishing a diagnosis of systemic onset 
Juvenile idiopathic arthritis (SOJIA). Also to be noted is the fact that whenever SOJIA is 
associated with macrophage activation syndrome, ferritin levels are strikingly high and 
usually exceeds 10,000 ng/ml, thus acting as a good biomarker for diagnosis of SOJIA 
and macrophage activation syndrome. 
Interleukin 18 (IL 18) is a unique cytokine which belongs to Interleukin 1 family. It is 
present in epithelial cells, blood monocytes and keratinocytes. Interleukin 18 induces 
production of Interferon gamma by Natural killer cells and T cells and also induces 
production of Tumor necrosis alpha and chemokine secretion by macrophages. Normal 
levels of circulating IL 18 in the serum of healthy individuals are 100 pg/ml. Its levels are 
elevated in conditions associated with systemic inflammation such as SOJIA (35).   In 
systemic onset juvenile idiopathic arthritis, the levels of interleukin 18 are elevated out of 
proportion as compared to other cytokines. In conditions where SOJIA is complicated by 
Macrophage activation syndrome, levels of circulating IL18 are elevated more than 
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tenfold.  Studied have also proven that levels of circulating IL 18 correlates strongly with 
disease activity and was also found to be useful in predicting an upcoming flare of the 
disease(36). 
 
CALPROTECTIN: 
 
Calprotectinis a calcium- and zinc-binding protein of the S100/calgranulin family 
(37).S100 proteins constitute a family of acidic calcium-binding proteins thatare 
important in intracellular calcium metabolism. (38). In 1983, Dale et al originally 
discovered Calprotectinas an antimicrobial protein that was present in the cytoplasm of 
neutrophil granulocytes(39) . Later on, Sander et al and Roth et al described it as a 
promising marker of inflammation(40). Srikrishna et al, in their study, proved that the 
molecule is involved in the recruitment of inflammatory cells by interactions with 
endothelial cells(41).  
 
Calprotectin is also known in literature by other synonyms such as S100A8/A9, 
MRP8/14 (myeloid-related protein), calgranulin A/B, 27E10 antigen, cystic fibrosis 
antigen,and L1 protein and myeloid-histiocyte antigen. Calprotectin is mainly found in 
the cytoplasm of neutrophils (42). Its concentration in neutrophils is so abundant that it 
constitutes about half of total cytosolic protein(43). It can also be expressed on activated 
monocytes and macrophages and can be produced by bonemarrow cells, squamous 
epithelium (keratinizing and non-keratinizing), some mucosal epithelial cells, micro 
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vascular endothelial cells and fibroblasts.The normal level is in the range 1–6 mg/l, and it 
increases in response to various tissue injuries and inflammation(44). 
 
The term Calprotectin is used to describe a complex of two calciumbinding proteins of 
the S100 family, S100A8 and S100A9. The human S100A8 protein (also known as 
myeloid-related protein 8, calgranulin A, or L1 light chain) is made up of 93 amino acids 
and has a molecular weight of 10.8 kd. The human S100A9 protein (MRP-14, calgranulin 
B, and L1 heavychain) consists of 114 amino acids with a molecular weight of 13.2 kd. 
Hence, Calprotectin is a 24kDa heterodimer composed of one light (MRP8) and two 
heavy (MRP14).Calprotectin also contains zinc-binding domains, with a zinc-binding 
capacity higher than other S100 proteins, and are not affected by the binding of 
calcium.Calprotectin also has antibacterial activity due to the presence of these histidine 
based zinc-binding sequences (His-X-X-X-His motif) (42).  It can be identified as a 
monomer, with separate chaining, or as a hetero- or homodimeric, trimeric or tetrameric 
complex (45). The genes for Calprotectin are located on the human chromosome 1q21 
(37). 
 
FECAL CALPROTECTIN: 
 
Calprotectin is a small calcium-binding protein belonging to the S100 family of proteins 
and contributes approximately 60% of the protein content of the cytosol in neutrophils. 
Polymorphonuclear neutrophils migrate to the intestinal mucosa from the circulation if 
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there is active intestinal inflammation. Any disturbance to the mucosal architecture due to 
the inflammatory process, results in leakage of neutrophils along with Calprotectin into 
the lumen leading to its subsequent excretion in feces. Calprotectin appears to be 
distributed homogeneously in feces and is stable for up to 7 days at room temperature. 
Multiple studies have hence looked at the usefulness of Calprotectin as a marker of 
intestinal inflammation. 
Inflammatory bowel disease (IBD) involves chronic inflammation of the digestive tract 
and consists of 2 distinct clinical entities called ulcerative colitis and crohns disease. 
FecalCalprotectin has been proposed as a useful biomarker for the differential diagnosis 
between IBD patients and healthy controls. A study done by Moein et al showed that 
fecalCalprotectin levels were increased in patients with inflammatory bowel disease 
compared to healthy controls  (p<0.05).  Fecal Calprotectin had a stronger correlation 
with disease endoscopic activity than conventional inflammatory markers (r=0.847 versus 
r= -0.44 for CRP and r=0.054 for ESR in Crohn's disease and r=0.798 versus r=0.463 for 
CRP and r=0.467 for ESR in ulcerative colitis). Receiver operating characteristic (ROC) 
curve analysis showed fecal Calprotectin has larger area under the curve  than 
conventional inflammatory markers (1 versus 0.849 for CRP and 0.846 for ESR)(46). 
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CALPROTECTIN IN RHEUMATOLOGICAL DISORDERS: 
 
The usefulness of Calprotectin as a biomarker in rheumatological disorders in an area of 
active research.  Currently, many studies have suggested  that Calprotectin is a potentially 
more sensitive marker of  disease activity in rheumatoid disorders than conventional 
inflammatory markers such as the erythrocyte sedimentation rate (ESR) and C-reactive 
protein (CRP), because it directly reflects inflammation in the synovium (47). Multiple 
studies have shown that alterations of Calprotectin level are associated with disease 
activity in patients with Still’s disease (48),  rheumatoid arthritis (RA)(47),  primary 
Sjögren’s syndrome (pSS) (49), ankylosing spondylitis (AS) (50), psoriatic arthritis (PsA) 
(51), juvenile idiopathic arthritis (JIA) (52) and systemic lupus erythematosus (SLE) 
(53). 
 
Garcia et al conducted a study on 60 patients with rheumatoid arthritis study with the 
objective to evaluate relationships between serum Calprotectin levels, disease activity, 
and response to treatment. Calprotectin was also investigated as a predictive marker of 
clinical response. They found that Calprotectin levels correlated with rheumatoid factor 
levels (r = 0.25; p <0.05). In their studyCalprotectin levels at baseline were not predictive 
of response to treatment but significantly decreased during treatment in responders (p < 
0.0001). They concluded that Calprotectin levels correlated with clinical and laboratory 
assessments of joint inflammation and also decreased in response to treatment, indicating 
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that Calprotectin is a  marker for assessment and monitoring of disease activity in patients 
with RA(47). 
Similar studies to find the relationship between Calprotectin levels and rheumatoid 
arthritis were also carried out by Choi et al and Inciarte Mundo et al. Their studies 
focused on using Calprotectin as a marker of response to treatment with biological agents 
in patients with Rheumatoid arthritis.  In their study, Choi et al recruited 170 patients 
with rheumatoid arthritis who were on treatment with adalimumab, Rituximab or 
infliximab and measures Calprotectin levels at baseline and also at 4 and 16 weeks after 
initiation of treatment. Patients were divided into clinical responders and non-responders. 
In their study they found that treatment with adalimumab, infliximab or rituximab 
lowered the level of Calprotectin significantly in the combined group of good and 
moderate responders, but not in non-responders. In those patients receiving adalimumab 
or infliximab, this change already reached statistical significance after 4 weeks of 
treatment, suggesting that Calprotectin could be used to monitor the early response to 
tumor necrosis factor α inhibitors (anti-TNF-α) treatment and to predict subsequent 
clinical response. In those receiving rituximab, a statistically significant decrease in 
Calprotectin level was found after 16 weeks of initiation of treatment in responders, but 
not in non-responders(54). 
Inciarte-Mundo et al conducteda cross-sectional study on 87 patients with rheumatoid 
arthritis, receiving adalimumab, etanercept or infliximab for atleast 3 months and 
compared the accuracy of serum Calprotectin and acute-phase reactants such as C-
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reactive protein (CRP) and erythrocyte sedimentation rate (ESR) in stratifying disease 
activity and to correlate Calprotectin levels with tumor necrosis factor inhibitor trough 
serum levels. They found that Calprotectin stratified disease activity in rheumatoid 
arthritis patients receiving TNF-α inhibitors more accurately than the acute-phase 
reactants such as CRP and erythrocyte sedimentation rate (ESR) and alsoCalprotectin 
level correlated inversely with TNF-α inhibitors trough serum levels (55).  Inciarte-
Mundo et al did another study to determine the association between Calprotectin, ESR, 
CRP and disease activity indices in 33 patients with rheumatoid arthritis receiving 
tocilizumab and found that serum Calprotectin level was higher in patients than in 
healthy controls. In their study, Calprotectin levels did not differ according to age or sex 
andCalprotectin level strongly correlated with all composite disease activity indices 
compared to ESR and CRP (56).  
Guo et al studied the usefulness of Calprotectin in patients with adult onset still’s disease 
(AOSD) and concluded that Calprotectin has a sensitivity of 63% and specificity of 
80.1% for the diagnosis of adult onset still’s disease. The positive rate of Calprotectin 
was significantly higher in AOSD cases compared to patients with other diseases 
(systemic lupus erythematosis, primary Sjogrens syndrome, rheumatoid arthritis  etc.) 
and healthy controls (p < 0.001)(48). 
Haga et al conducted a cross-sectional study of 100 patients with systemic lupus 
erythematosus (SLE) and found that Calprotectin levels were higher in patients than in 
matched controls (3661 micrograms/l versus 1051 micrograms/l; P < 0.001). They also 
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found that Calprotectin was the only laboratory parameter with significant association to 
the disease activity index SLEDAI (r = 0.28; P < 0.01). In their study, Calprotectin levels 
were higher in SLE patients with anti-DNA antibodies compared to patients without anti-
DNA antibodies (4501 micrograms/l versus 3279 micrograms/l; P = 0.01) and those 
patients with arthritis were noted to have higher serum levels of Calprotectin than those 
without arthritis (7652 micrograms/l versus 2811 micrograms/l; P < 0.01) and hence 
indicating that the serum Calprotectin level is also indicative of arthritis activity in 
patients with SLE.(53). In 2016, Tantivitayakul et al studied the usefulness of 
Calprotectin (also known as MRP 8 or 14) and reported that myeloid-related proteins 
MRP8 and MRP14 significantly correlated with the early loss of the kidney function in 
SLE patients and with their therapeutic response. They concluded that MRP-8 and -14 
can be used as non-invasive  biomarkers to assess prognosis in patients with lupus 
nephritis(57). Tydén et al measured serum Calprotectin levels in 237 systemic lupus 
erythematosus patients with clinically inactive disease and found that elevated serum 
levels of Calprotectin in systemic lupus erythematosus (SLE) patients may be used as an 
indicator of severe cardiovascular disease. They also suggested that those SLE patients 
with elevated Calprotectin levels may benefit from more intense cardiovascular primary 
preventive strategies and introduction of early immunosuppressive treatment(58). 
Serum Calprotectin levels were also studied in other rheumatologic conditions such as 
Behcets disease which is a form of systemic Vasculitis, Kawasaki disease and in 
polymyalgia rheumatica or temporal arteritis.Oktayoglu et al conducted a study on 
48 
 
patients with Behcets disease and concluded that even though serum Calprotectin levels 
were higher in patients with Behcets disease compared to healthy controls, it did not 
correlate well with other inflammatory markers such as ESR and CRP and also did not 
serve as a good marker for assessment of disease activity or quality of life in patients with 
Behcets disease(59).  
Hirono et al studied the usefulness of Calprotectin as marker of disease activity and 
severity of coronary artery lesion development in patients with acute Kawasaki disease. 
They studied 61 patients with acute Kawasaki disease and concluded that serum 
Calprotectin levels as well as mRNA expressions of Calprotectin in granulocytes were 
strongly up regulated during the early stage of acute Kawasaki disease, and their levels 
decreased dramatically within 24 hours of intravenous immune globulin therapy (p < 
0.05) in 45 responders. Furthermore, in 16 non-responders both of these increased after 
the initial treatment. They also found that the number of Calprotectin positive circulating 
endothelial cells was higher in patients with acute Kawasaki disease than in control 
patients, especially in those patients in whom coronary artery lesions developed(60).   
Brun et al analyzed Calprotectin levels in patients with polymyalgia rheumatica and 
temporal arteritis and found that Calprotectin levels correlated well with other acute 
phase reactants and ESR and hence could be used as a marker of disease activity. They 
also found that Calprotectin levels decreased after starting oral steroids in these patients 
and its levels correlated with daily usage of prednisolone(61).     
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CALPROTECTIN IN JUVENILE IDIOPATHIC ARTHRITIS: 
 
Calprotectin is a good marker of inflammation and assessment of its usefulness as a 
marker of disease activity is an area of active research. 
Bojko in his study compared bloodCalprotectinlevels in patients with systemic-onset, 
polyarticular, rheumatoid factor-negative and Oligoarticular subtypes of 
juvenileidiopathicarthritis (JIA). He also tried to find if any link existed between 
bloodCalprotectinlevels and clinical and laboratory markers of disease activity. Bojko 
found higher Calprotectin levels in patients with systemic-onset subtype of the disease 
(median 13,800 ng/ml), which differed significantly from levels in healthy children 
(median 1,800 ng/ml, p = 0.00002), levels in patients with articular subtypes of JIA 
(median 2,700 ng/ml, p = 0.000008), and patients with RF-negative polyarthritis (median 
3,800 ng/ml, p = 0.003226) and oligoarthritis (median 2,500 ng/ml, p = 0.000009). 
Newly diagnosed patients with systemic onset juvenile idiopathic arthritis had the highest 
Calprotectinlevels, the median being 32,500 ng/ml (range: 13,800-177,000 ng/ml). Direct 
correlations were found between bloodCalprotectin and activity score (p = 0.000009), 
ESR (p = 0.000079) and CRP (p = 0.000058)(62). 
 
Systemic onset Juvenile Idiopathic arthritis is a disease that can mimic other conditions 
such as malignancies and infectious diseases and can pose a diagnostic challenge in the 
evaluation of pyrexia of unknown origin. Hence, Frosch at al studied the differences in 
Calprotectin levels in patients with systemic onset juvenile idiopathic arthritis, 
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malignancies and infectious diseases. They found that serum Calprotectin concentrations 
were significantly (P < 0.001) elevated in patients with active systemic-onset JIA (mean 
+/- 95% confidence interval 14,920 +/- 4,030 ng/ml) compared with those in healthy 
controls (340 +/- 70 ng/ml), patients with acute myeloblastic leukemia (840 +/- 940 
ng/ml), patients with systemic infections (2,640 +/- 720 ng/ml), patients with acute 
lymphoblastic leukemia (650 +/- 280 ng/ml). Serum Calprotectin levels distinguished 
systemic-onset JIA from infections with a specificity of 95% and was found to be a better 
marker than C reactive protein and hence could be used as an excellent tool for the 
diagnosis of systemic-onset JIA, allowing early differentiation between patients with 
systemic-onset JIA and those with other inflammatory diseases(63). 
Wittkowski et al(64) studied Calprotectin levels in children with juvenile idiopathic 
arthritis, systemic infections, malignancies (acute myeloblastic leukemia and acute 
lymphoblastic leukemia) andneonatal-onset multisystem inflammatory disease (NOMID). 
They found that mean levels of Calprotectin was much higher in children with juvenile 
idiopathic arthritis as compared to other above mentioned conditions and the sensitivity 
and specificity of  Calprotectinto distinguish between systemic-onset JIA and infections 
were 66% and 94%, respectively(64). 
 Shenoi et al(65), in their study found that the median level of Calprotectin in patients 
with systemic-onset JIA was 38,600 ng/ml whereas it was 4,700 ng/mlin patients with a 
non-systemic disease course.Calprotectin levels were significantly elevated in systemic 
onset juvenile idiopathic arthritis with >80% sensitivity and >90% specificity(65). 
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Holzinger et al (66)not only looked at the usefulness of Calprotectin as a marker of 
disease activity in children with juvenile idiopathic arthritis, they also analyzed if it could 
be used to predict disease relapse. They found that serum Calprotectin levels increased 
significantly (p<0.001) (mean±95% CI 12.030±3.090 ng/ml) during disease flares 
compared with patients with inactive disease (864±86 ng/ml). During periods ofclinical 
remission, Calprotectinlevels of >740 ng/ml was able to predict disease flares accurately 
with a sensitivity of 92% and specificity of 88%. Calprotectin levels also correlated well 
with clinical disease activity, as assessed by physician's global assessment of disease 
activity (r=0.62), Childhood Health Assessment Questionnaire (r=0.56), active joint 
count (r=0.46) and with C-reactive protein (r=0.71) and erythrocyte sedimentation rate 
(r=0.72) (for all p<0.001)(66). Schulze et al conducted a similar study to assess the 
usefulness of Calprotectin to predict disease flare in children with Juvenile Idiopathic 
arthritis. Calprotectin levels in patients before relapses were significantly higher than the 
levels in patients in stable remission for one year (662 ng/ml versus 395 ng/ml; p < 0.05). 
Using a cut-off for Calprotectinof 450 ng/ml the likelihood ratio for relapse was 3.7 with 
a positive predictive value of 80% (67) . 
Frosch et al(68) conducted a study to assess the usefulness of Calprotectin as a marker of 
inflammatory activity in children with pauci-articular juvenile idiopathic arthritis. . In 
their study, they found significantly higher concentration of Calprotectin in synovial fluid 
(mean 42,800 ng/ml) compared with serum (2,060 ng/ml). Calprotectin levels in serum 
correlated well with those in synovial fluid (r = 0.78) and showed a strong correlation 
52 
 
with disease activity (r = 0.62). In those patients who responded to therapy 
(triamcinolone injection), the serum concentrations of MRP8/MRP14 decreased 
significantly, whereas no differences were found in patients who showed no clinical 
benefit. The postulated reason for the above findings were that infiltrating neutrophils 
and monocytes within the inflamed joints strongly expressed Calprotectin which were 
specifically released during interaction of activated monocytes with tumor necrosis 
factor-stimulated endothelial cells and their Secretion was mediated via an increase in 
intracellular calcium levels in monocytes(68).  
Only few Indian studies have looked at the role of Calprotectin in Juvenile Idiopathic 
arthritis. Rahman et al from Sanjay Gandhi post graduate Institute of medical sciences 
analyzed Calprotectin levels in patients with enthesitis related arthritis. In their study 
Median plasma levels of Calprotectin was 10 862.3 ng/ml which was much higher than 
controls (4426.1 ng/ml, P < 0.0001). Patients with active disease (11 669.5 ng/ml) had 
higher levels as compared with inactive disease (4421.8 ng/ml, P < 0.0001). They also 
noticed that plasma Calprotectin levels decreased on follow-up after 3 months only in 
patients who responded to treatment (P = 0.012) and Calprotectin levels were higher in 
synovial fluid as compared to plasma(69) 
A study done by Walscheid at al analyzed if Calprotectin could be used as a marker to 
predict intraocular inflammation in children with juvenile idiopathic arthritis associated 
uveitis. SerumCalprotectinlevels were elevated in patients with juvenile idiopathic 
arthritis associated uveitis as compared to nonuveitic controls (P< 0.05). In juvenile 
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idiopathic arthritis associated uveitis patients (JIAU), Calprotectinlevels correlated with 
age and age at onset of uveitis. A longitudinal analysis in JIAU patients showed a 
correlation of serum Calprotectinlevels with uveitis activity (P = 0.03) (70).  
Some studies have also analyzed if Calprotectin could be used to prognosticate response 
to certain drugs such as methotrexate and biological agents in patients with juvenile 
idiopathic arthritis. Moncrieffe at al (71) measured Calprotectin levels in a subgroup of 
patients with juvenile idiopathic arthritis prior to starting methotrexate therapy and 
demonstrated that patients with baseline Calprotectin levels greater than 3000 ng/ml were 
more likely to respond to methotrexate with an odds ratio of 16.07 and hence concluded 
that high levels of baseline serum Calprotectin have prognostic value in predicting a 
subgroup of patients whose arthritis will improve on methotrexate (71).  
Anink et al tested the predictive value of serumCalprotectin levels in patients on 
treatment with tumour necrosis factor blocking agents (TNF blockers) to identify 
responders to treatment and also to see if it could predictrelapse after discontinuation of 
therapy. They found thatbaseline Calprotectinlevels were higher in responders (median 
Calprotectin level of 1466 ng/ml) compared to non-responders (median Calprotectin of 
812 ng/ml, p < 0.001). Calprotectin levels decreased after commencement of treatment 
only in responders (p < 0.001). Calprotectin levels (p = 0.031, median 1025 ng/ml) were 
found to be higher in patients who flared within 6 months after discontinuation of 
treatment compared to patients with stable remission (median of 505 ng/ml) and hence 
concluded that higher levels of baseline Calprotectin was associated with good response 
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to anti-TNF treatment, whereas elevated Calprotectin levels at discontinuation of 
Etanercept was associated with higher chances to flare(72). 
Thus, there are many studies from around the world regarding the various aspects of 
Calprotectin in multiple diseases and especially in JIA. But, studies analyzing 
Calprotectin as a marker of disease activity in Indian children are very few and hence we 
undertook the below mentioned study.   
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AIM 
 
To assess the usefulness of serum Calprotectin level as a marker of  
disease activity in children with Juvenile Idiopathic arthritis 
 
OBJECTIVES 
 
 
Primary Objective: To assess the usefulness of serum Calprotectin levels as a marker of  
disease activity in children with Juvenile Idiopathic Arthritis. 
 
Secondary Objective: To prove that serum Calprotectin levels is a better predictor of disease  
activity in children with JIA compared to ESR and CRP which are the present laboratory  
parameters used for assessment of disease activity. 
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MATERIALS AND METHODOLOGY 
 
Study Design 
Cross sectional study 
Study Period 
Children were recruited over a period of one and half years from April 2016 to 
September 2017 
Study setting 
Participants of this study were recruited from the Paediatric Rheumatology clinic of 
Christian Medical College, Vellore, India.  The Paediatric Rheumatology outpatient 
department (OPD) functions on 3 week days (Wednesdays, Fridays and Saturdays) a 
week. The OPD serves on an average of about 60-90 patients every week.  
 
Participants 
Inclusion Criteria 
Children diagnosed to have with JIA below the age of 16 years who fulfilled the International 
League of Associations for Rheumatology (ILAR) classification criteria for juvenile idiopathic 
arthritis (1). 
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Exclusion criteria  
A) Children whose parents/local guardians did not give consent for recruitment into the study 
were excluded 
 
B) Children with Inflammatory bowel disease, Kawasaki disease, Systemic Lupus     
Erythematosus and cystic fibrosis will be excluded as they can also have high 
Calprotectin levels. 
 
Data Collection and methodology: 
Children with Juvenile Idiopathic arthritis who presented serially to the pediatric rheumatology 
OPD in the above mentioned setting and time period and also fulfilled the inclusion criteria were 
recruited into the study. Clinical and relevant demographic data will be obtained from the 
participants directly into clinical proforma which contained details  such as age, sex, disease 
duration, disease subtype, disease activity and laboratory parameters such as blood counts, ESR, 
CRP and Calprotectin levels . 
Blood samples were collected for complete blood count, ESR and CRP which are the laboratory 
parameters being currently sent as standard of care for all patients with Juvenile Idiopathic 
Arthritis. In addition, blood for serum Calprotectin levels were also withdrawn by venipuncture 
method after obtaining consent from the parents for children below 12 years of age and assent 
from children above 12 years of age. Blood counts, ESR and CRP values were analysed on the 
same day. However, samples for Calprotectin analysis was stored in the department of clinical 
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microbiology in a temperature of -20 degree Celsius and all Calprotectin samples were analysed 
over a period of 2 days at the end of study period after recruitment of all the study patients. The 
laboratory values of the participants were obtained from the hospital patient information system. 
Patients were divided into active and inactive group based on disease activity at the end of the 
study. The laboratory personnel analyzing the Calprotectin level were blinded about the disease 
activity status of the patients. 
 
Laboratory analysis: 
Complete blood count: Sample was sent in an EDTA tube and sent to the clinical 
pathology laboratory. Blood was processed in the Beckwith coulter machine and the 
validated results were considered.ESR was evaluated according to the Westergren 
method (cut-off 20mm/h).  
Serum CRP: Measured by nephelometry assay; normal values ranged from 0.1 to 0.6 
mg/dl. 
Serum Calprotectin:  
Serum Calprotectin levels were measured by sandwich-enzyme linked immune sorbent 
assay technology (ELISA) by using a ―Human Calprotectin ELISA Kit‖ produced by 
Wuhan Fine Biological Technology Company limited.  . 
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Principle of the Assay: 
This kit was based on sandwich enzyme-linked immune-sorbent assay technology. Anti- 
Calprotectin antibody was pre-coated onto 96-well plates. And the biotin conjugated anti-
Calprotectin antibody was used as detection antibodies. The standards, test samples and 
biotin conjugated detection antibody were added to the wells subsequently, and washed 
with wash buffer. HRP-Streptavidin was added and unbound conjugates were washed 
away with wash buffer. TMB substrates were used to visualize HRP enzymatic reaction. 
TMB was catalyzed by HRP to produce a blue color product that changed into yellow 
after adding acidic stop solution. The density of yellow is proportional to the Calprotectin 
amount of sample captured in plate. The O.D. absorbance was read at 450nm in a 
microplate reader, and then the concentration of Calprotectin could be calculated. 
 
Materials Required: 
1.Human Calprotectin ELISA Kit (Kit components: ELISA micro Plate, lyophilized 
standard, dilution buffer, biotin labeled antibody, antibody dilution buffer, HRP- 
streptavidin conjugate, SABC dilution buffer, TMB substrate, Stop dilution, wash buffer, 
plate sealer) 
2. Microplate reader (wavelength: 450nm) 
3. 37°C incubator  
4. Automated plate washer  
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5. Precision single and multi-channel pipette and disposable tips  
6. Clean tubes and Eppendorf tubes  
7. Deionized or distilled water  
 
Washing and sample collection for assay: 
 All wells were aspirated and plates were washed 3 times with 350ul wash buffer. After 
the final wash, plate was inverted, and plates were clapped on absorbent filter paper or 
other absorbent material. Washer was set for a soaking time of 1 minute. 
Serum samples were allowed to clot for 2 hours at room temperature or overnight at 4°C 
before centrifugation for 20 minutes at approximately 1000×g. The supernatant was 
collected and assay was carried out immediately. Blood collection tubes were disposable, 
non-pyrogenic, and non-endotoxin  
 
Dilution Factor: The dilution factor used for this assay was 1:20 
Reagent Preparation and storage: 
All reagents were brought to room temperature before use.  
1, Wash Buffer:  
30mL of Concentrated Wash Buffer was diluted into 750 mL of Wash Buffer with 
deionized or distilled water. Unused solution was put back at 4°C. The solution was 
cooled to room temperature before use.  
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2, Standard:  
1). 1000ng/ml of standard solution: 1 ml of Sample / Standard dilution buffer was added 
into one Standard tube, and the tube was kept at room temperature for 10 min and mixed 
thoroughly. 
 
2).500ng/ml→15.63ng/ml of standard solutions: Label 6 Eppendorf tubes with500ng/ml, 
250ng/ml, 125ng/ml, 62.5ng/ml, 31.25ng/ml, 15.63ng/ml, respectively. 0.3 ml of the 
Sample / Standard dilution buffer was added into each tube.  0.3 ml of the 
above1000ng/ml standard solution was added into 1st tube and mixed thoroughly. 0.3 ml 
from 1st tube to 2nd tube was added and mixed thoroughly. Transfer 0.3 ml from 2nd 
tube to 3rd tube and mixed thoroughly, and so on.  
3, Preparation of Biotin-detection Antibody working solution  
This was prepared within 1 hour before the experiment.  
1) Calculate the total volume of the working solution: 0.1 ml / well × quantity of wells. 
(Allow 0.1-0.2 ml more than the total volume)  
2) Dilute the Biotin-detection antibody with Antibody dilution buffer at 1:100 and mix 
thoroughly.(i.e. Add 1 μl of Biotin-detection antibody into 99 μl of Antibody dilution 
buffer.)  
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4, Preparation of HRP-Streptavidin Conjugate (SABC) working solution:  
This was prepared within 30min before the experiment.  
1) Calculate the total volume of the working solution: 0.1 ml / well × quantity of wells. 
(Allow 0.1-0.2 ml more than the total volume)  
2) Dilute the SABC with SABC dilution buffer at 1:100 and mix thoroughly. (i.e. Add 1 
μl of SABC into 99 μl of SABC dilution buffer.)  
 
Assay Procedure  
Before adding to wells, the SABC working solution and TMB substrate was euilibrated 
for at least 30 min at room temperature (37 °C). When diluting samples and reagents, 
they were mixed completely and evenly and a standard curve was plotted for each test. 
 
1. Standard, test sample and control (zero) wells were set on the pre-coated plate 
respectively, and then, their positions were recorded. It is recommend to measure each 
standard and sample in duplicate. Plates were washed 2 times before adding standard, 
sample and control (zero) wells!  
2. Aliquot 0.1ml of 1000ng/ml, 500ng/ml, 250ng/ml, 125ng/ml, 62.5ng/ml, 31.25ng/ml, 
15.63ng/ml, standard solutions into the standard wells.  
3. 0.1 ml of Sample / Standard dilution buffer was added into the control (zero) well.  
4. 0.1 ml of properly diluted serum sample was added into test sample wells.  
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5. The plate was sealed with a cover and incubated at 37 °C for 90 min.  
6. The cover was removed and the plate content was discarded, the plate was clapped on 
the absorbent filter papers or other absorbent material.  
7. 0.1 ml of Biotin-detection antibody working solution was added into the above wells 
(standard, test sample & zero wells). The solution at the bottom of each well was added 
without touching the side wall.  
8. The plate was sealed with a cover and incubated at 37°C for 60 min.  
9. The cover was removed and plate was washed 3 times with Wash buffer.  
10. 0.1 ml of SABC working solution was added into each well, the plate was covered 
and incubated at 37°Cfor 30 min.  
11. Remove the cover and wash plate 5 times with Wash buffer, and each time let the 
wash buffer stay in the wells for 1-2 min.  
12. 90 μl of TMB substrate was added into each well, the plate was covered and 
incubated at 37°Cin dark within 15-30 min.  And the shades of blue can be seen in the 
first 3-4 wells (with most concentrated Calprotectin standard solutions), the other wells 
show no obvious color.  
13. Add 50 μl of Stop solution into each well and mix thoroughly. The color changes into 
yellow immediately.  
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14. Read the O.D. absorbance at 450 nm in a microplate reader immediately after adding 
the stop solution.  
 
For calculation, (the relative O.D.450) = (the O.D.450 of each well) – (the O.D.450 of 
Zero well). The standard curve can be plotted as the relative O.D.450 of each standard 
solution (Y) vs. the respective concentration of the standard solution (X). The 
Calprotectin concentration of the samples can be interpolated from the standard curve by 
using professional software curve expert .Since the samples measured were diluted, the 
dilution factor was multiplied to the concentrations from interpolation to obtain the 
concentration before dilution. 
Summary  
1. Plate is washed 2 times before adding standard, sample and control (zero) wells!  
2. 100μL standard or sample is added to each well for 90 minutes at 37°C. Aspirate and 
wash plate 2 times.  
3. add 100μL Biotin-detection antibody working solution to each well for 60 minutes at 
37°C  
4. Aspirate and wash 3 times  
5. Add 100μLSABCworking solution to each well. Incubate for 30 minutes at 37°C  
6. Aspirate and wash 5 times  
7. Add 90μLTMB substrate. Incubate 15 -30 minutes at 37°C  
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8. Add 50μL Stop Solution. Read at 450nm immediately  
9. Calculation of results  
 
Statistical Methods: 
 
Continuous variables such as ESR and CRP were described as mean with standard 
deviation or median and interquartile range (IQR), and categorical variables  as 
frequencies with percentages. The diagnostic performance of Calprotectin level was 
assessed by plotting ROC for active and non-active cases. ROC was also plotted for 
diseased and healthy controls and the cut off with a good sensitivity and specificity was 
chosen.Spearman’s rank correlation coefficient was applied to correlate Calprotectin with 
disease activity . The comparison of ESR. CRP and Calprotectin across active and 
inactive disease was done using Mann Whitney U test as the distribution of the variables 
was slightly skewed which was assessed using QQ plot.  The sensitivity and specificity of 
ESR, CRP and Calprotectin were obtained for best cut off values using ROC curve. The 
area under ROC curves for ESR, CRP and Calprotectin levels was compared to find 
which among the three serves as a good marker of disease activity. ESR, CRP and 
Calprotectinwere correlated using Pearson’s correlation or Spearman’s correlation. 
Box plots were presented for the distribution of continuous variables across active and 
inactive groups. P value < 0.05 was considered as statistical significance. SPSS 16 was 
used for analyzing the data. 
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RESULTS 
  
121 children were recruited during study period. Baseline demographics and blood 
investigations recorded were analysed. At the end of the study, Children with Juvenile 
Idiopathic Arthritis (JIA) were divided into two groups. Group I was JIA children with 
active disease (n=68) and Group 2 was JIA children with inactive disease (n=58) as 
assessed by Wallace criteria. We also estimated Calprotectin levels in 10 normal children. 
Table 1: Demographic characteristics of all children (n=121) 
Parameter Number             (%) 
(n =121) 
Gender Male 68           (56%) 
Female 53        (44%) 
Mean age at diagnosis (years) 11.15 ± 3.75 
Diagnosis 
 Oligoarticular JIA 
 Polyarticular RF pos 
 Polyarticular RF neg 
 Enthesitis related arthritis  
 SOJIA 
 
 8             (7 %) 
 4             (3%) 
 37           (31%) 
 20           (16%) 
 52           (43%) 
Disease duration (years) 3.86 ± 2.64 ( 1 – 14) 
Disease status 
 Active 
 Remission on drugs 
 Remission off drugs 
 
 63           (52%) 
 57           (47%) 
 1             (1%) 
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Table 2: Baseline Characteristics of Active and Inactive disease 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Baseline characteristics                        JIA (n=121) 
Disease status Active disease  
       (n= 63) 
Inactive disease 
            (n= 58) 
Age (years) 
 
   11.30±3.88        11.00±3.60 
           JIA SUBTYPE: 
  Oligoarticular 
  RF + Polyarticular JIA 
  RF – Polyarticular JIA 
  Systemic JIA 
  ERA  
 
3 
1 
13 
37 
9 
 
5 
3 
24 
15 
11 
Hemoglobin  gm/dl 10.02±1.46         12.04±1.77 
Platelet (cu mm) 453819 ± 146032    324034 ±114691 
Total Count   19782 ± 29612        9191 ± 2836 
ESR (mm/hour)     46.71±17.14         14.24±8.07 
CRP (mg/dl)    100.65±69.83           3.07±0.26 
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Table 3: Mean and standard deviation of Calprotectin in various groups:  
Calprotectin 
(ng/ml) 
Normal children 
(n=10) 
Active Disease 
(n=63) 
Remission 
(n=58) 
P value 
Mean (ng/ml) 
Range(ng/ml) 
233 ±220 
86-764 
3954 ± 3220 
651- 14310 
1899± 1765 
160 – 7780 
˂ 0.001 
 
Mean value of Calprotectin was much higher in children with active disease as compared 
to children with inactive disease. Children with active disease had Calprotectin levels 
which were 2 fold higher than those with inactive disease. Children with inactive disease 
had Calprotectin levels which were in turn, 8 times higher than children who were normal 
healthy controls.  Calprotectin values in all groups (active disease, inactive disease and 
healthy controls) were statistically significant (p = ˂0.001). 
  
69 
 
Fig 1: Box Plot ofCalprotectin Values in children with active disease, remission and 
in normal children
 
Horizontal lines show the medians; boxes show the interquartile ranges; vertical lines 
show the high and low values. 
Mean Calprotectin levels in children with active disease was 3954 ng/ml and those in 
inactive disease was 1899ng/ml. Mean calprotectin levels in normal healthy children was 
only 233ng/ml. The above box plot clearly indicates that Calprotectin levels were much 
higher in children with active disease when compared to children with inactive disease 
and healthy children. 
p = ˂0.001 
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Fig 2: ROC curve analysis showing the diagnostic performance of Calprotectin for 
discriminating patients with active JIA from patients with inactive disease: 
 
 
The Area under the curve for Calprotectin was 0.744 . For a value of 1760 ng/ml, 
Calprotectin had a sensitivity of 77% and specificity of 61% .  
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Fig 3: ROC curve of Calprotectin in children with oligoarticular and polyarticular 
JIA
 
Area under the curve for Calprotectin in children with Oligoarticular and polyarticular 
JIA( RF +ve and RF –ve ) was 0.797 . In children with the above mentioned subtype, a 
Calprotectin value of 1468ng/ml had a sensitivity of 82% and specificity of 69%  
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Fig4: ROC curve of Calprotectin in children with Enthesitis related arthritis 
 
 
Area under the curve for Calprotectin in children with Enthesitis Related Arthritis ( HLA 
+ve and HLA –ve ) was only 0.414 . In children with the above mentioned subtype, a 
Calprotectin value of 2141ng/ml had a sensitivity of 77% and specificity of 28%  
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Fig5: ROC curve of Calprotectin in children with Systemic onset JIA 
 
 
Area under the curve for Calprotectin in children with Systemic onset JIA was 0.768 . In 
children with the above mentioned subtype, a Calprotectin value of 1111ng/ml had a 
sensitivity of 86 % and specificity of 60 %  
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Fig6: Comparison of ROC curve of ESR, CRP and Calprotectin: 
 
The area under the curve for CRP, ESR and Calprotectin were 1.0, 0.944 and 0.744 
respectively. Hence, based on the ROC curve, it can be inferred that ESR and CRP are 
better markers of disease activity as compared to Calprotectin.  
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Fig 7: Scatter plot of correlation between ESR and Calprotectin 
 
 
Based on the scatter plot, it can be inferred that there was only weak correlation between 
ESR and Calprotectin. r value was 0.295 and p value was ˂0.001 
 
 
 
P value˂0.001 
R value = 0.295 
Serum Calprotectin levels 
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Fig 8: Scatter plot of correlation between CRP and Calprotectin 
 
 
There was only a weak correlation between CRP and Calprotectin with an r value of 
0.426 and p value˂0.001 
 
 
 
 
 
 
P value˂0.001 
R value = 0.426 
Serum Calprotectin levels 
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DISCUSSION 
 
As mentioned in the introduction, JIA is the most common chronic rheumatic disorder of 
childhood.  Even though, clinical criteria for JIA to differentiate active and inactive 
disease are fairly well defined, there is lack of reliable laboratory criteria which can 
differentiate disease activity. Various biomarkers which can reliably predict disease 
activity are currently under research. Calprotectin is one such marker which is currently 
under extensive research. We undertook this study to assess the usefulness of 
Calprotectin as marker of disease activity in Indian children with juvenile idiopathic 
arthritis. 
Demographic Characteristics: 
We studied a total of 121 children with juvenile idiopathic arthritis. In our study, there 
was a slight preponderance of males who constituted 56% of the study population as 
compared to females who constituted 44% of study population. This was in consistence 
with the results published by Porkodi et al who studied clinical profile of JIA in children 
from South India and showed a male preponderance of 62%.(73). Singh et al studied the 
clinic immunological profile of children with JIA in North India (Chandigarh) and found 
a male preponderance of 64%.(74) 
Male:female ratio in our study was 1.2:1. This resonated with similar ratios demonstrated 
by Saurenmann et al in their study of ethnicity as a risk factor in children with JIA. In 
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their study, they found that the male:female ratio in children with JIA of Asian descent 
was 1:1. (75) 
The mean age at diagnosis in our study, taking into account all 121 children was 11.15 ± 
3.75 years.  
In our study, 52% of children had systemic onset JIA constituting the maximum number. 
Children with polyarticular, pauciarticular and enthesitis related arthritis constituted 41%, 
8% and 20% of our study population respectively. In a study done by Viswanatha Kumar 
et al who studied 112 children with JIA, 9 % had systemic onset, 63% had polyarticular 
onset and 36 % had pauci-articular onset JIA(76). Similarly, Seth et al studied the clinic 
immunological profile of 361 children with JIA.The frequency of occurrence of systemic, 
pauciarticular and polyarticular disease in their study was 24%, 30% and 46% 
respectively(77). Although, it is difficult to provide an explanation for these differences, 
it may be related to the different genetic backgrounds of the populations under study. It is 
known that some HLA haplotypes are closely associated with certain subtypes of JIA. 
These differences might also have occurred because the studies done by Viswanatha 
Kumar et al and Seth et al did not take children with enthesitis related arthritis into 
consideration in their studies. Maximum number of children in our study had systemic 
onset JIA, this might have been because of the fact that, children with systemic onset JIA 
have more frequent follow up and hospital visits as part of our treatment protocol 
compared to children with other subtypes because of their disease severity.  
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In our study, the mean value of Calprotectin in children with active disease (all disease 
subtypes included) was 3954 ng/ml and that in inactive disease was 1899 ng/ml. This 
difference was statistically significant (p=<0.001). The mean value of Calprotectin levels 
in normal healthy controls was233 ng/ml. Thus, Calprotectin levels in patients with 
inactive disease were 8 times more than in normal healthy controls. Children with active 
disease had 2 fold increased levels of Calprotectin as compared to children with inactive 
disease. Badot et al(78) conducted a study in Belgium and measured Calprotectin levels 
in 95 children with Juvenile Idiopathic arthritis. The findings of their study were closely 
similar to that of ours. Badot et al found that patients with inactive JIA had a 4-fold 
increased level of serum Calprotectin (6.555 ng/mL) compared to healthy controls (1.737 
ng/mL), while patients with active JIA had themselves a 2-fold increased level of serum 
Calprotectin (11.403 ng/mL) compared to patients with inactive disease. 
 
The role of serum Calprotectin as a marker of disease activity in systemic onset juvenile 
idiopathic arthritis has been investigated in multiple studies.  In our study, Calprotectin 
was found to be an excellent marker of disease activity in children with systemic onset 
Juvenile Idiopathic arthritis. The mean value of Calprotectin in children with active 
disease was 4415 ng/ml which was significantly higher than the value of Calprotectin in 
children with inactive disease who had a mean Calprotectin value of 1901ng/ml. 
Calprotectin mean value in active disease was 18 times more than the mean value 
obtained in normal healthy controls (233ng/ml).  The median Calprotectin value in active 
and inactive disease groups in our study were 2740ng/ml and 1020 ng/ml respectively.  . 
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Findings similar to ours were found in the study done by Frosch et al(52). In their study, 
serum Calprotectin levels during active disease in patients with systemic-onset JIA were 
44-fold higher than those in healthy controls (mean 14,920 ng/ml versus 340 ng/ml). 
Patients with inactive disease had a mean value of  530ng/ml. Mean concentrations 
during active disease in patients with systemic-onset JIA were also significantly higher 
than those in patients with systemic infections (2,640 ± 720 ng/ml), acute lymphoblastic 
leukemia (650 ±280 ng/ml), acute myeloblastic leukemia (840 ±940 ng/ml), and NOMID 
(2,830 ±580 ng/ml) . However, such comparisons cannot be made in our study as we 
looked at Calprotectin values in children with juvenile idiopathic arthritis only and did 
not include children with other conditions as mentioned in Frosch’s study.  
 
 A study done by Holzinger et al(66) also resonated the fact that Calprotectin levels are 
very high in children with active disease as compared to those in disease remission with a 
mean Calprotectin value of 12030ng/ml during active phase of illness as against mean of 
864ng/ml during disease remission. Holzinger’s study also proved that during clinical 
remission, serum Calprotectin levels greater than740 ng/ml predicted disease flares 
accurately with a sensitivity of 92% and specificity of 88%. However, this specific aspect 
of Calprotectin as marker to predict a disease flare during a period of clinical remission 
was not looked at in our study. 
 
In our study, the area under the curve for Calprotectin in children with systemic onset JIA 
was 0.768. In children with systemic onset JIA, a Calprotectin value of 1111ng/ml had a 
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sensitivity of 86 % and specificity of 60 %.  Shenoi et al(65) studied various biomarkers 
in children with systemic onset JIA and in their study, Calprotectin levels were 8 times 
higher in children with active systemic onset JIA as against children with inactive 
disease. The area under the curve for Calprotectin in their study was .86 with 80% 
sensitivity and 80% specificity. The difference in the specificity and AUC values 
between our study and Shenoi’s study might be because of differences in sample size 
between the 2 study groups. We had 52 children with systemic onset JIA in our study as 
against only 20 children in Shenoi’s study.   
 
In our study, Calprotectin levels correlated well with disease activity in children with 
oligoarticular juvenile idiopathic arthritis with mean value of 2738 ng/ml in children with 
active disease compared to a mean value of 428 ng/ml in children with inactive disease. 
The mean value of Calprotectin was 6 times more elevated in children with active disease 
as compared to those with inactive disease in oligoarticular JIA subgroup in our study. 
These findings were consistent with similar studies done elsewhere. Frosch et al 
(68)measured Calprotectin levels in children with oligoarticular JIA and found that 
Calprotectin levels were  up to 5 times higher in serum samples from patients with active 
disease (mean of 2,170ng/ml) compared with those in remission (mean of 405 ng/ml) . 
Those in remission showed levels that were only slightly elevated over the normal range 
(mean of 360 ng/ml). They also found that Calprotectin levels were much higher in 
synovial fluid as compared to serum and that serum levels of Calprotectin decreased after 
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treatment with intraarticular triamcinolone injections in patients who responded to 
therapy. However, such comparisons could not be made in our study as we did not look at 
these specific parameters such as synovial fluid Calprotectin levels or changes in 
Calprotectin levels with regard to drug therapy.  
 
In our study Calprotectin was not useful as a good marker of disease activity in children 
with Enthesitis related arthritis. The median Calprotectinlevel in active disease was 2466 
ng/ml and median Calprotectin level in inactive disease was 2710 ng/ml. However, in 
contrast, in a study done by Rahman et al in India(69), who measured Calprotectin levels 
in 69 patients with enthesitis related arthritis,Patients with active disease (11 669.5 ng/ml) 
had higher levels Calprotectin as compared with inactive disease (4421.8 ng/ml, 
P<0.0001). There is no logical explanation as to why median levels of Calprotectin were 
lower in the active disease group as compared to inactive disease group in our study. 
 
In our study, apart from analyzing the values of Calprotectin with regard to disease 
activity, we also compared Calprotectin with ESR and CRP which are the current 
biomarkers being used for assessment of disease activity. In our study, there was weak 
correlation between ESR and Calprotectin with r value of 0.295 and p value was ˂0.001. 
Similarly, weak correlation was found between CRP and Calprotectin with r value of  
0.426 and p value ˂0.001. These findings of ours were consistent with a study done by 
Bojka et al(62) where weak correlation was found between ESR and Calprotectin with a 
83 
 
p value of 0.000079 and r value of 0.450. Like in our study, only weak correlation existed 
between CRP and Calprotectin with a p value of 0.000058 and r value of 0.480. 
 
Thus, our study proves the usefulness of serum Calprotectin levels as a good marker of 
disease activity in children with Juvenile Idiopathic arthritis except in the enthesitis 
related arthritis subgroup. However, we could not prove that Calprotectin was better than 
ESR and CRP as a disease activity biomarker as claimed by other studies from various 
parts of the world.  
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LIMITATIONS 
 
There were a few limitations to our study: 
1. Firstly, considering the fact that the objective of the study was to assess the usefulness 
of Calprotectinas a biomarker of disease activity in children with JIA, collection of serial 
samples in same children would have been ideal. Comparisons based on sequential 
sampling may have provided additional information on the accuracy of these markers.  
2. Secondly, since we studied Calprotectin levels in JIA as a whole, there was unequal 
distribution of patients in various disease subsets. This might have had a few implications 
on the results of this study. 
3. In our study, all serum samples for measurement of Calprotectin were analysed on a 
single day, and hence, samples had been stored in Microbiology lab for periods ranging 
from 1 month to 1 year. The implication of storage and its effect on estimated values of 
Calprotectin during analysis remains unknown. 
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SUMMARY OF RESULTS 
 
 121 children with JIA were recruited into the study, 63 had active disease and 58 
had inactive disease.  
 Systemic onset JIA constituted 42% of the study population and was the 
predominant disease subtype.  
 Mean Calprotectin value in active disease (3954ng/ml) was 2 fold higher than 
those with inactive disease (1899ng/ml) (p value ˂0.001) and 16 times higher than 
children who were normal healthy controls(mean of 233ng/ml).   
 For a cut off value of 1760 ng/ml, Calprotectin had a sensitivity of 77% and 
specificity of 61% for assessment of disease activity in JIA.  
 Calprotectin was best suitable as a disease marker for systemic onset subtype of 
JIA where it had an area under the curve of 0.768 and for a cut off  value of 
1111ng/ml, had a sensitivity of 86 % and specificity of 60 %.  
 However, Calprotectin correlated very poorly with ESR and CRP with r values of 
0.295 and 0.426 respectively.. 
  Hence, from our study, we can conclude that Calprotectin is a good marker of 
disease activity in children with JIA. However, it was not superior to ESR or CRP.    
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CONCLUSION 
 
To conclude, our data suggest that Calprotectin levels are increased in the plasma of JIA 
children and plasma Calprotectin correlates with disease activity.  However, it was not 
found to be superior to ESR and CRP. But, it seems logical to suspect that Calprotectin 
will be a better marker for follow up of disease activity in patients receiving biological 
therapy as these drugs act against cytokines such as TNF-α, interleukin-1 and interleukin 
16 which will reduce the circulating cytokines and thus levels of acute phase reactants 
such as ESR and CRP. Thus, we need more studies in Indian population which involve 
sequential sampling of the same study population in their various phases of disease 
activity and also look at the effect of biological agents and other medications on the 
levels of these biomarkers which will enable us to precisely understand the accuracy of 
these biomarkers.  A prospective study with a longer follow-up will help establish the 
role of Calprotectin in monitoring disease activity and predicting flares. 
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Christian Medical College, Vellore 
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Department of Pediatrics 
 
Study Title: Serum Calprotectin Levels as a marker of disease activity in children 
with Juvenile Idiopathic Arthritis 
 
Study Information sheet 
 
You are being requested to participate in a study to measure Calprotectin levels in blood for the 
estimation of disease activity in children with Juvenile Idiopathic Arthritis 
What is Juvenile Idiopathic arthritis (JIA)? 
Juvenile Idiopathic arthritis is one of the common rheumatic diseases affecting children less 
than 16yrs of age. It is a systemic inflammatory disorder involving synovial joints. Characteristic 
features of JIA include painful swelling of the joints with painful restriction of the movements, 
lasting for more than six weeks of duration. JIA is further classified into different subtypes 
based on the number of joints involved. JIA is treated with Non-steroidal anti-inflammatory 
drugs, Disease modifying antirheumatic drugs, biological agents or steroids based on the 
disease status. 
 
What is Serum Calprotectin? Why is it important to estimate its level? 
Inflammation is a process in which white blood cells and chemicals help protect us from 
infection and foreign substances such as bacteria and viruses. In some diseases, however, the 
body's defence system (immune system) triggers an inflammatory response when there are no 
foreign substances to fight off which is called autoimmune diseases, where the body's normally 
protective immune system causes damage to its own tissues 
JIA is an autoimmune disease affecting a large number of children. Even today, there are no 
reliable laboratory tests for assessment of disease activity in JIA. Hence, there are a number 
tests undergoing research for assessment of disease activity in JIA. . Serum Calprotectin is one 
such test. 
Calprotectin is a protein found in blood and is released by leucocytes (white blood cells) during 
periods of inflammation as occurs in JIA. Western studies have proved Calprotectin levels are 
increased in children with JIA.  But studies in Indian Children are lacking. Our aim is to prove 
Calprotectin levels in blood will aid as a marker for assessment of disease activity in children 
with JIA. If proved by our study, it will help in the diagnosis and management of children with 
JIA in the future. 
If you take part what will you have to do? 
If you agree to participate in this study, your child will be enrolled into the study. Blood samples 
will be taken for CBC, ESR, CRP and serum Calprotectin by simple venipuncture method. There 
are nil adverse effects for this simple procedure except minimal pain at the time of blood draw.   
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Can you withdraw from this study? 
Your participation in this study is entirely voluntary and you are also free to decide to withdraw 
permission to participate in this study. If you do so, this will not affect your child’s usual 
treatment at this hospital in any way.  
 
What will happen if you develop any study related injury? 
Study related injury is very unlikely as this study involves blood sampling by simple 
venipuncture method which is minimally invasive.  
Will you have to pay for the treatment and investigations?  
Yes. You have to pay for Complete Blood Count, ESR and CRP which are routine tests being currently 
done at CMC for your child’s assessment and treatment. Serum Calprotectin levels will be done as part 
of this study and you do not have to pay for this test.  
 What happens after the study is over? 
Once test is performed, your child can continue the treatment as advised. Being enrolled in this 
study will not affect your child’s treatment in any way.. 
Will your personal details be kept confidential? 
The results of this study will be published in a medical journal in the future but your child will 
not be identified by name in any publication or presentation of results. However, your medical 
notes may be reviewed by people associated with the study, without your additional 
permission. 
 
Who to contact in case of any further study related doubts? 
If you have any further clarifications, kindly contact  
Dr. Anish Sam George, 
PG Registrar, 
Department Of Child Health, 
CMC, Vellore 
Mob: 9840868253 
E-mail: dr.anishsam@gmail.com 
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Christian Medical College, Vellore 
Department of Pediatrics 
 
CONSENT TO TAKE PART IN THE STUDY 
 
Study Title:  Serum Calprotectin Levels as a marker of disease activity in children with 
Juvenile Idiopathic Arthritis. 
 
Study Number:  
Participant’s name: 
Date of Birth / Age (in years): 
 
I_____________________________________________________________ 
___________, father/mother/guardian of  ___________________________________ 
 
(Please tick boxes) 
Declare that I have read the information sheet provided to me regarding this study and have 
clarified any doubts that I had. [ ] 
 
I also understand that my child’s participation in this study is entirely voluntary and that I am 
free to withdraw permission to participate in this study at any time without affecting my child’s 
usual treatment or his/her legal rights [ ] 
 
I also understand that during the study, I will have to pay for blood investigations like Complete 
blood count, ESR and CRP. [ ] 
 
I understand that this study involves taking by child’s blood samples by venipuncture method [ ] 
 
I understand that the study staff and institutional ethics committee members will not need my 
permission to look at my child’s health records even if I withdraw from the trial. I agree to this 
access [ ]  
 
I understand that my child’s identity will not be revealed in any information released to third 
parties or published [ ]  
 
I voluntarily agree and give consent for my child to take part in this study [ ] 
 
Name of parent/guardian:                                                                    Investigator’s Name: 
Signature:                                                                       Investigator’s Signature:      
Date: 
 
Name of witness: 
Relation to participant: 
Date: 
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Christian Medical College, Vellore 
Department of Pediatrics 
CHILD ASSENT FORM 
 
Study Title: Serum Calprotectin Levels as a marker of disease activity in children 
with Juvenile Idiopathic Arthritis 
 
 
Study No: 
Name: 
Age: 
Date Of Birth: 
 I understand that this study involves estimation of serum Calprotectin levels for 
assessment of disease activity in children with Juvenile Idiopathic Arthritis. 
 I understand that if I am enrolled in this study, it involves collection of my blood 
samples by venipuncture method. 
 I understand that my participation in the study is voluntary and that I amfree to 
withdraw from the study at any time, without giving any reason and without my 
medical care being affected.  
 I understand that the study team, the Ethics Committee and the regulatory 
authorities will not need my permission to look at my health records for the current 
study. I agree to this access. However, I understand that my identity will not be 
revealed in any information released to third parties or published. 
 I have been explained about the study in detailand have had the opportunity to ask 
questions 
 I agree to take part in the above study 
 
Your Name:                                                                                              Investigator’s Name: 
Your Signature:                                                                                      Investigators Signature: 
Date: 
 
Parents Signature / Thumb Impression   
103 
 
ChristianMedicalCollege, Vellore 
Department of Pediatrics 
 
Study Title:  Serum Calprotectin Levels as a marker of disease activity in children with Juvenile 
Idiopathic Arthritis 
Study Proforma 
Study No:           Date :  
Name: 
Age 
Sex: 
Hospital No: 
Disease duration: 
Diagnosis: JIA Types: Oligoarticular/Polyarticular RF +/Polyarticular RF -/Enthesitis related 
arthritis/psoriatic arthritis/systemic onset JIA 
Disease activity: Active disease/Remission on medications/Remission off medications 
Laboratory Values: 
Hemoglobin: 
Total Count: 
Differential Count: 
Platelet count: 
ESR: 
CRP: 
Serum Calprotectin Level: 
 
 
slno date age sex diseasedur diagnosis diseaseact hb tc
1 03/08/2016 6 1 6 3 1 8.6 9500
2 02/08/2016 9 1 1 4 1 8.6 23500
3 19/08/2016 16 1 13 7 1 8.6 9200
4 19/08/2016 14 1 3 7 1 9 8000
5 18/08/2016 14 2 6 3 1 9.9 8500
6 17/08/2016 6 2 2 7 1 7.1 12200
7 02/09/2016 3 2 2 7 1 9 10100
8 23/09/2017 12 2 1 3 1 11.2 8700
9 22/09/2016 16 1 6 7 1 11 9100
10 23/09/2017 10 2 6 7 1 6.9 11400
11 17/10/2016 6 2 2 1 1 10.8 9600
12 21/10/2016 8 2 3 7 1 8.8 10800
13 21/10/2016 12 2 4 7 1 8.1 19600
14 11/11/2016 14 1 3 7 1 11 37700
15 11/11/2016 14 2 7 7 1 9.2 20500
16 11/11/2016 6 1 1 7 1 10.9 14900
17 11/11/2016 14 2 1 3 1 10.2 9200
18 12/11/2016 13 2 1 7 1 9.2 28200
19 17/11/2016 5 1 1 7 1 10.4 31300
20 28/11/2016 15 1 6 3 1 10.9 10000
21 30/11/2016 13 1 5 7 1 9.3 6300
22 30/11/2016 16 1 7 7 1 9.7 17200
23 02/12/2016 14 1 3 2 1 10.6 11300
24 11/12/2016 16 1 6 4 1 10.9 12100
25 30/11/2016 11 1 2 5 1 11.5 18600
26 01/12/2016 16 1 2 4 1 10.4 8000
27 01/12/2016 5 1 4 3 1 7.6 15400
28 08/12/2016 14 1 6 3 1 8.7 6900
29 03/08/2016 6 1 1 7 2 12.3 17000
30 03/08/2016 13 1 4 3 2 13.1 7000
31 05/08/2016 10 2 2 3 2 11.8 12700
32 17/08/2016 11 2 2 3 2 13.3 10100
33 23/08/2016 16 1 9 4 2 2 7100
34 02/09/2016 11 1 1 3 2 11.4 10800
35 02/09/2016 10 1 6 7 2 12.7 11600
36 22/09/2016 8 2 4 2 2 10.5 11300
37 20/09/2016 12 1 3 3 2 12.2 7400
38 11/11/2016 15 2 4 7 2 12.6 11800
39 11/11/2016 12 2 9 3 2 12.5 10500
40 12/11/2016 7 2 1 1 2 11.2 7800
41 10/11/2016 7 2 5 1 2 11.9 12400
42 18/11/2016 2 2 1 1 2 10.2 17200
43 17/11/2016 13 1 1 4 2 13.3 5700
44 18/11/2016 7 2 2 3 2 12.9 7100
45 22/11/2016 10 2 1 7 2 13.4 5200
46 23/11/2016 8 2 6 3 2 14 6900
47 23/11/2016 16 2 4 1 2 10.4 6100
48 01/12/2016 10 1 4 7 2 11.1 10100
49 02/12/2016 7 2 2 1 2 11.3 10200
50 02/12/2016 12 1 4 3 2 11.9 9300
51 02/12/2016 16 1 5 3 2 15.7 8300
52 02/12/2016 10 2 9 3 2 11.9 5600
53 08/12/2016 9 1 3 7 2 12 6800
54 21/12/2016 7 1 6 3 2 12 9000
55 08/12/2016 16 1 2 4 1 11.8 10700
56 24/01/2017 13 2 7 3 1 9.7 8800
57 24/01/2017 11 2 1 7 1 9.1 39400
58 16/01/2017 10 2 7 7 1 10.7 11800
59 16/01/2017 3 2 1 7 1 6.9 24300
60 21/01/2017 10 2 1 3 1 10.6 18200
61 20/01/2017 8 2 4 7 1 8.8 17000
62 27/01/2017 14 2 3 7 1 10.9 9700
63 06/01/2017 13 1 6 7 1 11.2 150000
64 06/01/2017 15 2 4 7 1 11.4 12100
65 06/01/2017 7 1 6 1 1 6.1 200000
66 05/01/2017 9 1 6 7 1 9.6 28800
67 02/02/2017 6 1 4 7 1 8.7 12000
68 01/02/2017 5 2 1 7 1 10.2 16500
69 08/02/2017 4 1 2 3 1 9.3 17800
70 08/02/2017 10 2 3 1 1 12.4 11500
71 10/02/2017 8 2 1 3 1 10.1 9700
72 10/02/2017 13 1 4 4 1 11.7 9000
73 02/03/2017 14 2 2 7 1 10.5 16500
74 21/04/2017 16 2 5 7 1 11.4 10900
75 23/06/2017 15 1 1 3 1 11.8 14600
76 21/04/2017 16 1 7 5 1 12.3 8300
77 20/04/2017 15 1 1 3 1 11.9 10300
78 19/04/2017 15 1 1 7 1 9.4 18800
79 02/03/2017 7 1 2 7 1 10.4 12500
80 03/03/2017 16 1 14 7 1 12.1 7300
81 16/03/2017 13 1 7 7 1 13.3 23700
82 23/03/2017 12 1 1 4 1 10.8 9000
83 23/03/2017 14 1 3 4 1 10.5 8900
84 24/03/2017 14 1 9 7 1 8.6 27400
85 21/03/2017 12 1 5 7 1 11.4 18500
86 29/03/2017 10 2 7 7 1 10.2 12400
87 28/03/2017 13 1 5 7 1 9.1 6700
88 16/12/2016 6 1 2 7 1 9.2 20300
89 08/12/2016 14 1 1 3 2 11.2 6000
90 28/12/2016 11 1 4 7 1 11.1 15100
91 28/12/2016 16 2 5 2 2 13.4 7200
92 24/01/2017 3 2 1 7 2 12.1 14600
93 27/01/2017 6 1 1 7 2 10.4 13100
94 27/01/2017 10 2 1 7 2 11.2 14300
95 27/01/2017 13 1 1 5 2 13.1 6900
96 27/01/2017 12 1 2 3 2 13.4 9600
97 27/01/2017 9 2 7 7 2 10.3 8700
98 05/01/2017 13 1 1 4 2 11 7100
99 06/01/2017 10 2 1 2 2 12.2 6600
100 06/01/2017 14 2 5 3 2 11.9 8400
101 06/01/2017 10 1 6 3 2 11.9 12200
102 05/01/2017 7 1 2 7 2 12.5 10900
103 11/01/2017 15 1 3 4 2 11.5 6200
104 03/02/2017 14 2 4 3 2 12.4 7600
105 02/02/2017 10 2 4 3 2 13.8 7300
106 30/01/2017 12 2 3 3 2 10.6 9500
107 10/02/2017 16 2 5 3 2 14.1 11000
108 10/02/2017 16 2 6 3 2 12.7 8000
109 21/04/2017 6 1 1 3 2 14.1 10300
110 21/04/2017 14 2 4 7 2 10.6 7000
111 21/04/2017 16 1 5 3 2 12.9 6800
112 21/04/2017 12 1 6 4 2 12.6 9900
113 20/04/2017 10 1 1 7 2 10.7 8400
114 17/03/2017 12 1 8 7 2 11.8 13500
115 23/03/2017 5 2 2 7 2 12.4 10400
116 21/03/2017 15 1 4 4 2 11.6 6700
117 22/03/2017 12 2 8 4 2 11.3 5500
118 11/04/2017 13 1 5 4 3 13.1 12200
119 12/04/2017 16 1 9 4 2 14.6 7100
120 23/06/2017 6 1 2 3 2 13.1 7100
121 22/06/2017 16 1 5 4 2 12.6 8000
dcn dcl dce platelet esr crp serum
69 16 0 609600 57 128 11970
65 23 0 684000 59 54 3146
57 34 1 398000 57 34 1420
56 34 2 665000 51 75 1000
83 13 1 410000 54 46 2228
57 32 1 728000 52 119 1703
38 54 1 533000 27 78 1693
48 45 1 547000 45 111 651
56 29 7 385000 43 16 1818
70 22 4 751000 59 170 2028
71 17 2 352000 60 61 1517
65 25 2 560000 56 36 2740
72 18 2 730000 79 163 1659
91 8 0 557000 41 201 1050
82 13 0 370000 59 136 1163
77 17 1 434000 61 190 1770
68 19 4 382000 48 20 1774
81 14 0 322000 9 161 1024
88 8 0 564000 54 119 2033
73 24 1 197000 52 148 1163
52 37 4 509000 52 61 7690
49 32 14 405000 38 15 769
62 28 1 594000 29 41 850
71 14 6 249000 43 169 2380
74 21 1 516000 44 44 2028
49 38 4 241000 60 45 1110
54 40 1 222000 90 77 6900
71 21 4 491000 67 107 3600
58 33 0 206000 6 3 1020
32 37 0 345000 5 3 680
50 37 3 419000 27 3 700
62 28 3 263000 37 3 860
32 43 14 340000 18 3 857
51 28 11 322000 9 3 780
81 12 0 221000 8 4 870
32 54 6 145000 16 3 525
55 35 4 178000 20 3 800
61 30 0 378000 3 3 980
59 34 1 495000 22 3 415
39 50 4 376000 17 3 240
55 38 2 360000 15 3 650
70 24 2 430000 28 3 953
53 35 1 212000 15 3 619
53 38 2 413000 20 3 818
38 47 8 254000 17 3 666
52 42 2 350000 4 3 663
58 34 0 248000 14 3 450
76 17 2 409000 5 3 810
50 36 8 606000 13 3 372
42 45 6 446000 10 3 378
55 31 3 217000 3 3 741
51 28 12 188000 25 3 16
38 20 7 191000 9 3 124
54 34 2 360000 10 3 599
75 18 1 306000 25 176 3006
57 37 1 480000 55 52 5762
82 6 0 370000 67 110 4928
80 15 0 573000 62 169 7138
79 18 0 380000 2 181 2398
81 13 0 610000 37 395 6534
57 36 2 670000 67 120 4792
51 41 2 390000 32 180 10528
88 6 6 540000 40 47 8864
73 19 1 468000 20 48 10904
56 36 0 106000 22 19 4608
85 9 1 310000 9 201 4014
81 14 1 340000 51 54 5598
80 15 0 286000 57 201 2366
51 36 7 640000 34 36 2201
75 17 0 510000 56 58 3960
50 36 2 392000 26 51 4048
58 34 2 370000 34 12 3797
78 15 0 429000 55 111 2045
74 21 0 590000 30 73 10900
80 12 2 403000 33 59 2513
75 17 1 240000 22 40 2255
67 22 2 280000 45 11 2780
49 36 5 711000 55 55 850
69 23 2 528000 53 201 3667
54 38 0 334000 26 80 14310
92 5 0 515000 35 57 3930
76 15 0 421000 32 92 2466
57 18 18 279000 53 38 2460
92 6 0 505000 55 101 5650
86 11 1 409000 58 201 4698
64 28 1 613000 57 127 11150
45 40 6 370000 71 76 3570
80 15 2 392000 67 170 2274
50 41 3 263000 38 3 2820
83 12 1 425000 54 114 9240
62 28 3 335000 17 3 388
49 42 3 522000 10 3 2660
59 32 3 690000 9 3 3600
78 16 0 460000 20 3 456
52 35 2 280000 8 3 3180
58 30 5 330000 17 4 7240
39 43 7 480000 14 3 712
28 50 14 284000 20 3 2340
55 33 3 374000 17 3 2140
58 30 4 274000 21 3 2400
43 33 19 386000 6 3 1420
52 39 3 260000 20 4 1750
61 30 2 279000 8 3 4160
50 35 4 306000 9 3 5620
49 40 3 287000 5 3 3660
44 42 9 176000 32 3 728
66 24 5 240000 9 3 2560
54 42 0 220000 9 3 622
34 53 6 375000 5 3 3600
45 45 2 370000 13 3 3120
60 30 4 270000 14 3 5700
47 40 7 409000 20 3 2660
58 28 7 358000 8 3 1060
70 22 1 465000 20 3 2920
52 35 7 405000 10 3 7780
46 40 4 270000 20 3 2760
40 54 1 218000 10 3 1360
34 28 30 84000 19 3 5620
38 42 10 281000 8 3 3200
23 59 7 328000 5 3 2080
42 43 5 143000 9 4 3220
